Настройки

Укажите год
-

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее
-

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Укажите год
Укажите год
Применить Всего найдено 1516. Отображено 100.
12-01-2012 дата публикации

UPPER STACK FOR A NUCLEAR MAGNETIC RESONANCE SPECTROMETER APPARATUS AND ASSOCIATED METHOD OF OPERATING A NUCLEAR MAGNETIC RESONANCE SPECTROMETER APPARATUS

Номер: US20120007599A1
Автор:
Принадлежит: THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC

An upper stack for a nuclear magnetic resonance spectrometer apparatus includes a cryostat having one or more chambers for holding samples in a frozen state. A sample loading tube that also allows He delivery extends to the cryostat, and a sample changer mechanism is disposable at least in part proximate to the cryostat for moving specimens from the cryostat to an NMR probe where they can be heated and melted using inductive heating. A sample ejection tube extends from the sample changer mechanism allowing a clear path for heating a sample in an NMR probe using a laser beam. 1. An upper stack for a nuclear magnetic resonance spectrometer apparatus , comprising:a cryostat having at least one sample-receiving chamber for holding a plurality of samples;a sample loading tube extending to said cryostat;a sample ejection tube; anda sample changer mechanism disposable at least in part proximate to said cryostat for moving samples from said at least one chamber to an NMR probe.2. The upper stack defined in claim 1 , further comprising a drive mechanism for shifting said specimens relative to said sample loading tube claim 1 , to enable delivery of successive samples to said cryostat.3. The upper stack defined in wherein said drive mechanism is a rotary drive claim 2 , said samples being disposed in a circular array in said cryostat claim 2 , said drive mechanism being configured to alternately index said samples into alignment with said sample loading tube.4. The upper stack defined in wherein said cryostat includes a port or passageway for receiving a cryogenic fluid claim 3 , said cryogenic fluid being conveyed to said port or passageway via said a delivery tube.5. The upper stack defined in wherein said sample changer mechanism includes a carrier shiftable for extracting a sample from said cryostat and for moving the extracted sample toward an axis of the NMR probe.6. The upper stack defined in wherein said carrier is shiftable in a first direction parallel to said axis ...

Подробнее
Номер записи: 1
26-01-2012 дата публикации

MYCOPLASMA GALLISEPTICUM FORMULATION

Номер: US20120021005A1
Автор: Ferguson Naola M., Kleven Stanley H.
Принадлежит: University of Georgia Research Foundation, Inc.

The present invention provides a formulation that prevents virulent galHsepticum infection in birds of the order GaIHf ormes. The formulation comprises live galHsepticum strain K5831 or derivatives thereof in a pharmaceutically acceptable carrier. A vaccine that prevents virulent galHsepticum infection in birds of the order Galliformes is also presented. Methods for administering the formulation and vaccine are also presented. 1Mycoplasma gallisepticumMycoplasma gallisepticumMycoplasma gallisepticum. An isolated strain , wherein the isolated strain is the K5831 strain deposited at the ATCC under Patent Designation PTA-9495.23-. (canceled)4Mycoplasma gallisepticumMycoplasma gallisepticum. An essentially biologically pure culture of the K5831 strain deposited at the ATCC under Patent Designation PTA-9495 , or a progeny or derivative thereof , wherein a progeny or derivative thereof has essentially the same biological and serological characteristics of the K5831 strain deposited at the ATCC under Patent Designation PTA-9495.5Mycoplasma gallisepticumMycoplasma gallisepticum. The isolated of claim 1 , wherein the isolated is lyophilized.6Mycoplasma gallisepticum. A composition comprising the isolated of .7. The composition of further comprising water.8. The composition of further comprising a pharmaceutically acceptable carrier.9. The composition of claim 6 , wherein the composition is formulated for mucosal administration.10. The composition of claim 6 , wherein the composition is formulated for intranasal claim 6 , intraocular claim 6 , or oral administration.11. The composition of claim 6 , wherein the composition is formulated for spraying or aerolizing.12Mycoplasma gallisepticum. A vaccine comprising the isolated of .13Mycoplasma gallisepticum. The vaccine of claim 12 , wherein the vaccine reduces the susceptibility of a birds of the order Galliformes to disease induced by strain.14Mycoplasma gallisepticumMycoplasma gallisepticum. A vaccine for birds of the order ...

Подробнее
Номер записи: 2
09-02-2012 дата публикации

IDENTIFICATION OF TOXIN-BINDING PROTEIN INVOLVED IN RESISTANCE TO CRY1 TOXINS, AND RELATED SCREENING METHODS

Номер: US20120034610A1
Автор: Adang Michael J., Jurat Fuentes Juan Luis, McNall Rebecca
Принадлежит: The University of Georgia Research Foundation, Inc .

The subject invention relates in part to the surprising and unexpected discovery that insects that are resistant to Cry toxins have measurably altered alkaline phosphatase (ALP) activity as compared to insects that are susceptible to Cry toxins. This and other surprising discoveries reported herein have broad implications in areas such as managing and monitoring the development of insect resistance to B. t. toxins. For example, the subject invention provides a simple and fast assay (enzymatic or otherwise) for detecting ALP activity levels and thereby monitoring the development of resistance by insects to crystal protein insect toxins. There was no prior motivation or suggestion to go about resistance monitoring using this simple and easy approach. 1Bacillus thuringiensislepidopteranslepidopteran: A method of screening a lepidopteran for resistance to a (B.t.) insecticidal Cry1 protein that is toxic to , wherein said is of a species known to develop resistance to said Cry1 protein , wherein said method comprises collecting a lepidopteran from a field of a B.t. crop , obtaining a gut cell membrane sample from said lepidopteran , measuring said sample for an amount of alkaline phosphatase enzymatic activity , and comparing said amount to a control level of alkaline phosphatase enzymatic activity determined from a gut cell membrane preparation from a control insect of known susceptibility to said Cry1 protein , wherein resistance to said Cry1 protein by said lepidopteran is indicated if said amount is less than that of a non-resistant insect , wherein said non-resistant insect is of the same genus and species as said lepidopteran.2: The method of wherein said method comprises running said sample on a gel claim 1 , and assessing said alkaline phosphates enzymatic activity of an approximately 68 kDa protein band on said gel.3: The method of wherein said enzymatic activity is measured optically.4: The method of wherein said Cry1 protein is a Cry1Ac protein.5: The method ...

Подробнее
Номер записи: 3
16-02-2012 дата публикации

GLYCOPEPTIDE AND USES THEREOF

Номер: US20120039984A1
Автор:
Принадлежит: University of Georgia Research Foundation, Inc.

A glycolipopeptide comprising a carbohydrate component, a peptide component and a lipid component, for use as a therapeutic or prophylactic vaccine. Also provided are monoclonal and polyclonal antibodies that recognize the glycolipopeptide of the invention, as well as uses thereof. 151-. (canceled)53. The glycolipopeptide of wherein the B-epitope is from a microorganism.54. The glycolipopeptide of wherein the microorganism is selected from the group consisting of a virus claim 53 , a bacterium claim 53 , a fungus claim 53 , and a protozoan.55. The glycolipopeptide of wherein the microorganism is a human immunodeficiency virus or a hepatitis C virus.56. The glycolipopeptide of wherein the B epitope is overexpressed on a cancer cell.57. The glycolipopeptide of wherein the carbohydrate component comprises a self-antigen.58. The glycolipopeptide of wherein the self-antigen comprises a MUC-1 glycopeptide.59. The glycolipopeptide of wherein the carbohydrate component comprises a viral antigen.60. The glycolipopeptide of wherein the viral antigen is from human immunodeficiency virus or a hepatitis C virus.61. The glycolipopeptide of wherein the carbohydrate component comprises a glycoconjugate selected from the group consisting of a glycosylated protein claim 52 , a glycosylated peptide claim 52 , a glycosylated lipid claim 52 , a glycosylated amino acid claim 52 , a DNA and an RNA.62. The glycolipopeptide of wherein the glycosylated peptide or glycosylated protein comprises a β-N-acetylglucosamine (β-O-GlcNAc) modified peptide.63. The glycolipopeptide of comprising a glycosylated peptide claim 52 , wherein the glycosylated peptide comprises the B-epitope and the T-epitope.64. The glycolipopeptide of wherein the carbohydrate component comprises a heparan sulfate fragment.65. The glycolipopeptide of wherein the lipid component comprises a Toll-like receptor (TLR) ligand.66. The glycolipopeptide of wherein the lipid component facilitates internalization of the ...

Подробнее
Номер записи: 4
16-02-2012 дата публикации

ALKYNES AND METHODS OF REACTING ALKYNES WITH 1,3-DIPOLE-FUNCTIONAL COMPOUNDS

Номер: US20120040011A9
Автор:
Принадлежит: University of Georgia Research Foundation, Inc.

1,3-Dipole-functional compounds (e.g., azide functional compounds) can be reacted with certain alkynes in a cyclization reaction to form heterocyclic compounds. Useful alkynes (e.g., strained, cyclic alkynes) and methods of making such alkynes are also disclosed. The reaction of 1,3-dipole-functional compounds with alkynes can be used for a wide variety of applications including the immobilization of biomolecules on a substrate. 23-. (canceled)4. The alkyne of wherein Rcomprises a covalently bound organic dye.5. (canceled)6. The alkyne of wherein X represents C═N—ORand Rrepresents an organic group having the formula —(CH)C(O)Y claim 1 , wherein:a is 1-3;{'sup': '5', 'Y represents OH or NHR; and'}{'sup': '5', 'Rrepresents hydrogen or a biotinylation product of a primary amine-containing organic group.'}7. The alkyne of wherein the biotinylation product is the biotinylation product of a primary amine-containing group of the formula —(CHCHO)(CH)-L—(CHCHO)(CH)NHand/or —(CDCDO)(CD)-L-(CDCDO)(CD)NH claim 6 , wherein b=0 to 100; c=0 to 100; d=0 to 100; e=0 to 100; f=0 to 100; and L is an optional cleavable linker.8. The alkyne of wherein the cleavable linker claim 7 , if present claim 7 , is a disulfide.9. The alkyne of wherein X represents CHORand Ris selected from the group consisting of an alkyl group claim 1 , an aryl group claim 1 , an alkaryl group claim 1 , and an aralkyl group.10. The alkyne of wherein Rrepresents —C(O)Z claim 9 , wherein:{'sup': 6', '7, 'Z represents an alkyl group, OR, or NHR;'}{'sup': 6', '7, 'Rand Rare each independently selected from the group consisting of an alkyl group, an aryl group, an alkaryl group, and an aralkyl group.'}11. The alkyne of wherein Ris a biotinylation product of a primary amine-containing organic group.12. The alkyne of wherein the biotinylation product is the biotinylation product of a primary amine-containing group of the formula —(CHCHO)(CH)-L- (CHCHO)(CH)NHand/or —(CDCDO)(CD)-L-(CDCDO)(CD)NH claim 11 , wherein b=0 to ...

Подробнее
Номер записи: 5
01-03-2012 дата публикации

Cyclopropenones and the Photochemical Generation of Cyclic Alkynes Therefrom

Номер: US20120053299A1
Автор: Locklin Jason, Poloukhtine Andrei A., POPIK VLADIMIR V.
Принадлежит: University of Georgia Research Foundation, Inc.

Cyclic alkynes (e.g., cyclooctynes such as dibenzocyclooctynes) can be photochemically generated from cyclopropenones as disclosed herein. The cyclic alkynes can be reacted (e.g., in situ) with materials having alkyne-reactive groups (e.g., azide groups in a “click” reaction). In preferred embodiments, the generation and reaction of the cyclic alkyne can proceed in the absence of a catalyst (e.g., Cu(I)). These reactions can be useful, for example, for the selective labeling of living cells that are metabolically modified with azido-containing surface monosaccharides, or for light-directed surface patterning. 2. The method of wherein the four atom bridge comprises carbon atoms claim 1 , oxygen atoms claim 1 , nitrogen atoms claim 1 , phosphorus atoms claim 1 , or combinations thereof.6. The method of wherein the method photochemically induces the ligation of the cyclic alkyne and the material comprising the alkyne-reactive group.7. The method of wherein the method forms a cyclic adduct.8. The method of wherein the material comprising the alkyne-reactive group is a 1 claim 7 ,3-dipole-functional compound.9. The method of wherein the cyclic adduct is a heterocyclic compound.10. The method of wherein the 1 claim 9 ,3-dipole-functional compound is selected from the group consisting of azide-functional compounds claim 9 , nitrile oxide-functional compounds claim 9 , nitrone-functional compounds claim 9 , azoxy-functional compounds claim 9 , acyl diazo-functional compounds claim 9 , and combinations thereof.11. The method of wherein the 1 claim 10 ,3-dipole-functional compound is an azide-functional compound claim 10 , and the cyclic adduct is a triazole.12. The method of wherein the material comprising the alkyne-reactive group is a diene claim 7 , and the cyclic adduct is a Diels-Alder adduct.13. The method of wherein the material comprising the alkyne-reactive group is a nitrosoarene claim 7 , and the cyclic adduct is an N-hydroxy indole.14. The method of wherein the ...

Подробнее
Номер записи: 6
08-03-2012 дата публикации

Feedback prodrug

Номер: US20120058960A1
Автор: Geert-Jan Boons, Jun Guo
Принадлежит: University of Georgia Research Foundation Inc UGARF

Compounds and methods for use in selectively inhibiting a lytic enzyme based on feedback inhibition are described. The conjugated compound serves as a substrate for a lytic enzyme. Cleavage of the conjugated compound by the lytic enzyme releases an inhibitor of the enzyme.

Подробнее
Номер записи: 7
08-03-2012 дата публикации

STABILIZED BIOACTIVE PEPTIDES AND METHODS OF IDENTIFICATION, SYNTHESIS, AND USE

Номер: US20120059145A1
Автор:
Принадлежит: University of Georgia Research Foundation, Inc.

An intracellular selection system allows screening for peptide bioactivity and stability. Randomized recombinant peptides are screened for bioactivity in a tightly regulated expression system, preferably derived from the wild-type lac operon. Bioactive peptides thus identified are inherently protease- and peptidase-resistant. Also provided are bioactive peptides stabilized by a stabilizing group at the N-terminus, the C-terminus, or both. The stabilizing group can be a small stable protein, such as the Rop protein, glutathione sulfotransferase, thioredoxin, maltose binding protein, or glutathione reductase, an α-helical moiety, or one or more proline residues. 1. A polypeptide comprising a bioactive peptide and a first stabilizing group coupled to a terminus of said bioactive peptide , wherein said first stabilizing group is heterologous to the bioactive peptide and lacks the capacity to participate in the formation of an intramolecular disulfide bond within the polypeptide.2. The polypeptide of claim 1 , wherein said polypeptide further comprises a second stabilizing group coupled to the other terminus of said bioactive peptide claim 1 , wherein the second stabilizing group is heterologous to the bioactive peptide.3. The polypeptide of claim 1 , wherein said first stabilizing group is coupled to the N-terminus of said bioactive peptide.4. The polypeptide of claim 1 , wherein said first stabilizing group is coupled to the C-terminus of said bioactive peptide.5. The polypeptide of claim 2 , wherein said first and said second stabilizing groups are the same.6. The polypeptide of claim 1 , wherein said first stabilizing group is coupled to said bioactive peptide via a peptide bond.7. The polypeptide of claim 2 , wherein said first and said second stabilizing groups are coupled to said bioactive peptide via peptide bonds.8. The polypeptide of claim 1 , wherein said bioactive peptide is selected from the group consisting of insulin claim 1 , glucagon claim 1 , calcitonin ...

Подробнее
Номер записи: 8
22-03-2012 дата публикации

ANTI-TRYPANOSOMAL PEPTIDES AND USES THEREOF

Номер: US20120070490A1
Автор: Hajduk Stephen L., Harrington John M.
Принадлежит: University of Georgia Research Foundation, Inc.

The present invention provides methods of killing, inhibiting the growth, and/or inhibiting the reproduction of kinetoplastid protozoan with hydrophobic signal sequence peptides and compositions including such hydrophobic signal sequence peptides. 1Trypanosoma. A method of killing a bloodstream form of a kinetoplastid protozoan of the genus , the method comprising contacting the protozoan with a hydrophobic signal sequence peptide , wherein the hydrophobic signal sequence peptide consists of about 12 to about 25 amino acid residues , and wherein the hydrophobic signal sequence peptide contains a positively charged amino acid at position minus five relative to the C-terminus of the hydrophobic signal sequence peptide.2. A method of treating or preventing a trypanosomal infection in a subject , the method comprising administering to the subject an effective amount of a hydrophobic signal sequence peptide , wherein the hydrophobic signal sequence peptide consists of about 12 to about 25 amino acid residues , and wherein the hydrophobic signal sequence peptide contains a positively charged amino acid at position minus five relative to the C-terminus of the hydrophobic signal sequence peptide.3. The method of claim 1 , wherein the hydrophobic signal sequence peptide has the sequence of an uncleaved signal sequence peptide of haptoglobin-related protein or paraoxonase 1.4. The method of claim 1 , wherein the hydrophobic signal sequence peptide is soluble in ethanol or dimethyl sulfoxide (DMSO).5. The method of claim 1 , wherein the hydrophobic signal sequence peptide comprises at least nine consecutive amino acid residues of MSDLGAVISLLLWGRQLFA (SEQ ID NO:1) claim 1 , MAKLIALTLLGMGLALFRNHQS (SEQ ID NO:3) claim 1 , a derivative of SEQ ID NO:1 claim 1 , or a derivative of SEQ ID NO:3 claim 1 , wherein a derivative of SEQ ID NO:1 or SEQ ID NO:3 has up to four hydrophobic amino acid residues of SEQ ID NO:1 or SEQ ID NO:3 exchanged for another hydrophobic amino acid claim 1 , ...

Подробнее
Номер записи: 9
22-03-2012 дата публикации

CHLORINE-FREE WATER TREATMENT

Номер: US20120071553A1
Автор: Doyle Michael P., Zhao Tong
Принадлежит: University of Georgia Research Foundation, Inc.

A combination of the surfactant SDS with levulinic acid produces a synergistic effect in relation to the antimicrobial effectiveness of the individual compounds, allowing the formulation of compositions wherein the active agents are present at concentrations effective to reduce bacterial and fungal counts in liquids, including, but not limited to, water and other beverages, without altering the organoleptic properties of the treated food substance. The active agents are FDA-approved as food additives, and the treated beverages can be any aqueous-based beverage consumable by humans or animals. The levulinic acid-SDS combination is also suitable for reducing or eliminating the microbial population on the surfaces of water and beverage containers, and the machinery and facilities for the bottling of liquids. 1. A method of reducing a microbial population of a liquid , the method comprising contacting the liquid with between about 0.5% to about 5% by weight per volume of levulinic acid and between about 0.05% to about 2% by weight per volume of sodium dodecyl sulfate (SDS) , wherein the levulinic acid and the SDS are effective in reducing the microbial load of the liquid.2. The method of claim 1 , wherein the liquid is suitable for consumption by an animal or human.3. The method of claim 1 , wherein the liquid has a pH value between about 0 and about 7.4. The method of claim 1 , wherein the liquid is water or a beverage.5. The method of claim 4 , wherein the beverage is a carbonated beverage.6. The method of claim 4 , wherein the beverage is a fruit juice.7. The method of claim 4 , wherein the beverage is an infusion.8. The method of claim 4 , wherein the beverage is selected from coffee or tea.9. The method of claim 1 , wherein the microbicidal levulinic acid and the SDS remain in the liquid after packaging of said liquid.10. A method for decontaminating a solid surface of a beverage manufacturing facility claim 1 , said method comprising the steps of contacting the ...

Подробнее
Номер записи: 10
05-04-2012 дата публикации

METHODS AND COMPOSITIONS USING FUNGAL LACCASES TO REDUCE TURF THATCH

Номер: US20120079764A1
Автор: Carrow Robert N., Huang Qingguo, Raymer Paul L., Sidhu Sudeep S.
Принадлежит: University of Georgia Research Foundation, Inc.

The present disclosure describes methods and compositions for reducing turf thatch and/or preventing turf thatch buildup. 1. A method of degrading turf thatch , comprising 'an isolated fungal laccase enzyme.', 'contacting the turf thatch with a composition comprising2. The method of claim 1 , wherein the laccase enzyme is from white rot fungi.3Trametes versicolor.. The method of claim 1 , wherein the laccase enzyme is from4. The method of claim 1 , wherein the composition further comprises a mediator.5. The method of claim 1 , wherein the mediator is chosen from the following: catechol claim 1 , guaiacol claim 1 , ABTS claim 1 , and violuric acid.6. The method of claim 1 , wherein the mediator comprises guaiacol.7. The method of claim 1 , wherein the enzyme is applied to the turf thatch in an amount of about 0.1 to about 20 units/cmof turf area.8. The method of claim 1 , wherein the enzyme is applied to the turf thatch in an amount of about 0.206 units/cmor more of turf area.9. The method of claim 1 , wherein the composition is applied to turf thatch at intervals ranging from one application about every 56 weeks to about once a week.10. A composition for reducing turf thatch comprising:a formulation comprising an isolated fungal laccase enzyme, wherein the formulation is adapted for application to turfgrass.11. The composition of claim 10 , wherein the formulation comprises:isolated fungal laccase enzyme andwater,wherein the formulation has a concentration of about 0.001% to 1% isolated laccase enzyme.12. A composition for reducing turf thatch comprising:a particulate topdressing, andan isolated fungal laccase enzyme, wherein the laccase enzyme is immobilized to particles of the particulate topdressing.13. The composition of claim 12 , wherein the topdressing is sand and wherein the isolated fungal laccase enzyme is immobilized to sand particles.14. The composition of claim 12 , wherein the laccase enzyme is immobilized to particles of the topdressing by a linking ...

Подробнее
Номер записи: 11
19-04-2012 дата публикации

METHODS AND COMPOSITIONS FOR DEGRADING PECTIN

Номер: US20120094347A1
Автор: Doran Peterson Joy
Принадлежит: University of Georgia Research Foundation, Inc.

The present invention provides enriched polynucleotides, and enriched polypeptides having pectinase activity. The present invention also includes methods of using the polynucleotides and polypeptides described herein. For instance, the methods include producing a metabolic product, such as ethanol. 134-. (canceled)35. An isolated polypeptide having pectinase activity , wherein the polypeptide comprises an amino acid sequence , wherein the amino acid sequence and the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4 have at least 80% identity.36. The isolated polypeptide of wherein the isolated polypeptide is expressed by a genetically modified microbe.37. The isolated polypeptide of wherein the microbe is a gram-negative microbe or a fungus.38E. coliS. cerevisiae.. The isolated polypeptide of wherein the microbe is or39. A composition comprising an enriched polypeptide having pectinase activity claim 36 , wherein the polypeptide comprises an amino acid sequence claim 36 , wherein the amino acid sequence and the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4 have at least 80% identity.40. A method for degrading pectin comprising:contacting a composition comprising pectin with a polypeptide having pectinase activity under conditions suitable for the degradation of the pectin, wherein the polypeptide comprises an amino acid sequence, wherein the amino acid sequence and the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4 have at least 80% identity, and wherein the pectin is degraded.41. The method of further comprising contacting the degraded pectin with a polypeptide having oligogalacturonate activity.42. The method of wherein the polypeptide is expressed by a genetically modified microbe claim 40 , and wherein the contacting comprises contacting the pectin with the genetically modified microbe.43. The method of wherein the genetically modified microbe expresses an exogenous polypeptide having oligogalacturonate activity.44. The method of wherein the genetically ...

Подробнее
Номер записи: 12
17-05-2012 дата публикации

VIRICIDAL AND MICROBICIDAL COMPOSITIONS AND USES THEREOF

Номер: US20120121679A1
Автор:
Принадлежит: University of Georgia Research Foundation, Inc.

The present disclosure encompasses compositions comprising a surfactant, and an acid such as, but not limited to, levulinic acid, that together have a synergistic effect in reducing the viability of a virus population compared to the efficacy of the individual compounds. This synergy allows the formulation of compositions where the active agents (including an acid and a surfactant) are present at concentrations effective to inactivate viruses on surfaces, including human skin. The viricidal compositions disclosed herein are efficacious without damaging the surface to which they may be applied, or even altering the organoleptic properties of a treated food substance. The viricidal compositions and wipes containing such compositions are suitable for sanitizing any surface suspected of having a viral load thereon, or where it is desirable to ensure that a viral load is as low as possible. 2. The antimicrobial composition of claim 1 , wherein the antimicrobial composition is formulated to be effective in reducing the viability of a virus selected from the group consisting of: a respiratory syncytial virus (RSV) claim 1 , a coronavirus claim 1 , an influenza virus claim 1 , a measles virus claim 1 , a Hepatitis B or C virus claim 1 , a Herpes simplex virus claim 1 , a norovirus claim 1 , a sapovirus claim 1 , an astrovirus claim 1 , a rhinovirus claim 1 , a rotavirus claim 1 , an adenovirus claim 1 , a Hepatitis E virus claim 1 , and a Hepatitis A virus.3. The antimicrobial composition of claim 1 , wherein the surfactant is an anionic surfactant selected from the group consisting of: sodium dodecyl sulfate claim 1 , sodium laureth sulfate claim 1 , cetylpyridinium chloride claim 1 , cetylpyridinium bromide claim 1 , and benzalkonium chloride.4. The antimicrobial composition of claim 1 , further comprising a gelling agent claim 1 , a foaming agent claim 1 , a soap claim 1 , a colorant claim 1 , a fragrance claim 1 , or any combination thereof.5. The antimicrobial ...

Подробнее
Номер записи: 13
24-05-2012 дата публикации

Chlorine-Free Liquid Microbicide Treatment

Номер: US20120129928A1
Автор:
Принадлежит: University of Georgia Research Foundation, Inc.

The combination of the surfactant SDS with levulinic acid produces a synergistic effect in relation to the antimicrobial effectiveness of the individual compounds. Accordingly, this surprising synergy allows the formulation of compositions wherein the active agents are present at concentrations effective to reduce bacterial counts in liquids, including, but not limited to, water and other beverages, especially those having a pH value less than about 7.0 by a factor between 10and 10without altering the organoleptic properties of the treated food substance. The active agents are FDA-approved as food additives, and the treated beverages can be any aqueous-based beverage consumable by humans or animals. 1. A method of reducing a microbial population of a liquid , the method comprising contacting the liquid with a microbicidal composition comprising: about 0.5% to about 20% by weight per volume of levulinic acid and about 0.05% to about 5% by weight per volume of sodium dodecyl sulfate (SDS); about 0.5% to about 10% by weight per volume of levulinic acid and about 0.05% to about 3% by weight per volume of sodium dodecyl sulfate (SDS); about 0.5% to about 5% by weight per volume of levulinic acid and about 0.05% to about 2% by weight per volume of sodium dodecyl sulfate (SDS); or about 0.5% to about 3% by weight per volume of levulinic acid and about 0.05% to about 1% by weight per volume of sodium dodecyl sulfate (SDS).2. The method of claim 1 , wherein the liquid is suitable for consumption by an animal or human.3. The method of claim 1 , wherein the liquid has a pH value between about 0 and about 7.4. The method of claim 2 , wherein the liquid is water or a beverage.5. The method of claim 4 , wherein the beverage is a carbonated beverage.6. The method of claim 4 , wherein the beverage is a fruit juice claim 4 , a vegetable-based beverage claim 4 , a sugar syrup claim 4 , a tea claim 4 , an infusion claim 4 , a coffee claim 4 , an isotonic drink claim 4 , a fermented ...

Подробнее
Номер записи: 14
07-06-2012 дата публикации

Control of Enterohemorrhagic E. Coli in Farm Animal Drinking Water

Номер: US20120141607A1
Автор: Doyle Michael P., Zhao Tong
Принадлежит: University of Georgia Research Foundation

The present invention relates to a new composition and methods for preventing the transmission of enterohemorrhagic and other foodborne pathogens to farm animals. In accordance with one embodiment, a composition comprising lactic acid and acidic calcium sulfate, and a compound selected from the group consisting of caprylic acid, sodium benzoate, butyric acid and chlorine dioxide is provided as an inhibitor of the growth of enterohemorrhagic and other foodborne pathogens. 15-. (canceled)6. An antimicrobial composition , wherein the composition comprises at least 0.05% lactic acid , at least 0.3% acidic calcium sulfate and at least 0.05% sodium benzoate.7. The composition of claim 6 , wherein the composition comprises about 0.05 to about 1.0% lactic acid claim 6 , about 0.3% to about 2.0% acidic calcium sulfate and about 0.05 to about 0.2% sodium benzoate.89-. (canceled)10E. coli. A method of decreasing enterohemorrhagic contamination of animal drinking water claim 6 , said method comprising adding an effective amount of a composition comprising lactic acid claim 6 , acidic calcium sulfate and sodium benzoate to said drinking water.11. The method of wherein the composition comprises about 0.05 to about 1.0% lactic acid claim 10 , about 0.3% to about 2.0% acidic calcium sulfate and about 0.05 to about 0.2% sodium benzoate.12E. coli. A method for inhibiting the transmission of enterohemorrhagic to farm animals claim 10 , said method comprising the steps of contacting farm feeding and watering equipment with a composition comprising lactic acid claim 10 , acidic calcium sulfate and sodium benzoate.13. The method of wherein the composition comprises about 0.05 to about 1.0% lactic acid claim 12 , about 0.3% to about 2.0% acidic calcium sulfate and about 0.05 to about 0.2% sodium benzoate.14. The method of wherein the farm equipment is contacted once a day with said composition.15. The method of wherein the farm equipment is contacted with the composition by spraying the ...

Подробнее
Номер записи: 15
07-06-2012 дата публикации

HEPARAN SULFATE SYNTHESIS

Номер: US20120142560A1
Автор:
Принадлежит: University of Georgia Research Foundation, Inc.

The invention provides an efficient modular chemical synthesis for heparan sulfate oligosaccharides based on orthogonal protection strategies. Modular disaccharide building blocks, themselves the product of a novel combinatorial synthesis, are combined in numerous ways to produce a range of oligosaccharides. 2. The disaccharide of wherein each of R claim 1 , Rand Ris independently a temporary protecting group or a permanent protecting group; wherein the permanent protecting group for Rand Ris selected from acetyl (Ac) claim 1 , benzyl (Bn) claim 1 , benzoyl (Bz) claim 1 , difluorobenzoyl claim 1 , (dfBz) claim 1 , pivaloyl benzoyl (PivBz) claim 1 , pivaloyl or anisoyl; and wherein the permanent protecting group for Ris Ac.3. The disaccharide of wherein Ris a protecting group selected from 9-fluorenylmethoxycarbonyl (Fmoc) claim 1 , allyloxycarbonyl (Alloc) claim 1 , [2 claim 1 ,2 claim 1 ,2-trichloroethoxycarbonyl] (Troc) claim 1 , levulinoyl (Lev) claim 1 , benzoyl (Bz) claim 1 , difluorobenzoyl claim 1 , (dfBz) claim 1 , pivaloyl levulinoyl (PivLev) claim 1 , pivaloyl benzoyl (PivBz) claim 1 , or a NAP ether.4. The disaccharide of wherein Ris different from R claim 1 , Rand R.5. The disaccharide of wherein Ris a temporary protecting group comprising a silyl or substituted silyl; or a permanent protecting group comprising methyl (Me) claim 1 , benzyl (Bn) claim 1 , 2-naphthylmethyl (NAP) or 1-naphthylmethyl (1-NAP).6. The disaccharide of wherein Ris a leaving group comprising trichloroacetimidate —C(NH)—CCl claim 1 , phenyltrifluoroacetimidate —C(NPh)—CF claim 1 , trifluoroacetimidate —C(NH)—CF; thioformimidate claim 1 , or S-glycosyl N-phenyltrifluoroacetimidate.7. The disaccharide of wherein Ris a temporary protecting group selected from 9-fluorenylmethoxycarbonyl (Fmoc) claim 1 , allyloxycarbonyl (Alloc) claim 1 , [2 claim 1 ,2 claim 1 ,2-Trichloroethoxycarbonyl] (Troc) claim 1 , trichloroacetyl (TCA) claim 1 , acetyl (Ac) claim 1 , phthalimido (Phthal) claim 1 ...

Подробнее
Номер записи: 16
14-06-2012 дата публикации

Antimicrobial Composition and Use as Food Treatment

Номер: US20120148716A1
Автор: Doyle Michael P., Zhao Tong
Принадлежит: University of Georgia Research Foundation

Antimicrobial compositions are provided comprising a pharmaceutically acceptable organic acid and a pharmaceutically acceptable surfactant. This synergistic combination allows compositions to be formulated at low concentrations that have efficacy in reducing bacterial counts by greater than 3 log within 5 minutes of contact while preserving the organoleptic properties of treated foods, including fresh produce. Also provided are methods for the use of the compositions to reduce the microbial load on the surfaces of foodstuffs, processed food products, and the hard surfaces of food preparation machinery, tools, benches, and the like. 1. A method of reducing a microbial population on the surface of a foodstuff , wherein the method comprises the step of contacting the foodstuff with an antimicrobial composition , said antimicrobial composition comprising a monoprotic organic acid having a carbon backbone of 4 to 10 carbons , a surfactant , and a solvent , for a time effective in reducing the viability or the cell density of the microbial population on the surface of a foodstuff.3. The method of claim 1 , wherein the monoprotic organic acid is levulinic acid.4. The method of claim 1 , wherein the surfactant is selected from the group consisting of: sodium dodecyl sulfate claim 1 , sodium laureth sulfate claim 1 , a quaternary ammonium cation claim 1 , cetyl pyridinium chloride claim 1 , and benzalkonium chloride.5. The method of claim 4 , wherein the surfactant is sodium dodecyl sulfate.6. The method of claim 1 , wherein the monoprotic organic acid is levulinic acid and the surfactant is sodium dodecyl sulfate.7. The method of claim 1 , wherein the composition comprises about 0.3 to about 3% levulinic acid by weight per volume of the antimicrobial composition claim 1 , and about 0.05% to about 2% sodium dodecyl sulfate by weight per volume of the antimicrobial composition.8. The method of wherein the antimicrobial composition is delivered to the foodstuff as a wash claim ...

Подробнее
Номер записи: 17
05-07-2012 дата публикации

ALKYNES AND METHODS OF REACTING ALKYNES WITH 1,3-DIPOLE-FUNCTIONAL COMPOUNDS

Номер: US20120172575A1
Автор:
Принадлежит: University of Georgia Research Foundation, Inc.

1,3-Dipole-functional compounds (e.g., azide functional compounds) can be reacted with certain alkynes in a cyclization reaction to form heterocyclic compounds. Useful alkynes (e.g., strained, cyclic alkynes) and methods of making such alkynes are also disclosed. The reaction of 1,3-dipole-functional compounds with alkynes can be used for a wide variety of applications including the immobilization of biomolecules on a substrate. 2. The compound of wherein Rrepresents a biomolecule.3. The compound of wherein the biomolecule is selected from the group consisting of peptides claim 2 , proteins claim 2 , glycoproteins claim 2 , nucleic acids claim 2 , lipids claim 2 , saccharides claim 2 , oligosaccharides claim 2 , polysaccharides claim 2 , and combinations thereof.4. The compound of wherein each Rrepresents hydrogen.5. The compound of wherein each Rrepresents hydrogen.6. The compound of wherein Rcomprises a covalently bound organic dye.7. The compound of wherein the organic dye is a fluorescent dye.9. The compound of wherein the biotinylation product is the biotinylation product of a primary amine-containing group of the formula —(CHCHO)(CH)-L-(CHCHO)(CH)NHand/or —(CDCDO)(CD)-L-(CDCDO) claim 8 ,(CD)NH claim 8 , wherein b=0 to 100; c=0 to 100; d=0 to 100; e=0 to 100; f=0 to 100; and L is an optional cleavable linker.10. The compound of wherein the cleavable linker claim 9 , if present claim 9 , is a disulfide.12. The compound of wherein the copolymeric group comprises a hydrophilic segment and a hydrophobic segment.13. The compound of wherein the copolymeric group comprises a fragment of the formula —[CHCHO]—[C(O)(CH)O]—H claim 11 , wherein n=0 to 100 and m0 to 100.14. A dibenzocyclooctyne having a biotin fragment attached thereto.17. A dibenzocyclooctyne having a covalently bound organic dye attached thereto.20. A dibenzocyclooctyne having a nanoparticle attached thereto.22. A method of preparing a heterocyclic compound claim 11 , the method comprising:{'claim-ref': ...

Подробнее
Номер записи: 18
26-07-2012 дата публикации

MICROBIAL VACCINE AND VACCINE VECTOR

Номер: US20120189657A1
Автор:
Принадлежит: University of Georgia Research Foundation, Inc.

The present invention includes cold-adapted, acid-fast bacterium for use as a vaccine and a vaccine vector. In preferred embodiments, the cold-adapted, acid-fast bacterium is a , for example, 1. A pharmaceutical composition comprising:an acid-fast bacterium with a maximum survival temperature of 30° C.; anda pharmaceutically acceptable carrier.2Mycobacterium shottsii, Mycobacterium pseudoshottsiiMycobacterium liflandii.. The pharmaceutical composition of wherein the acid-fast bacterium with a maximum survival temperature of 30° C. is selected from the group consisting of claim 1 , and3. A pharmaceutical composition comprising:{'i': 'Mycobacterium shottsii; and'}a pharmaceutically acceptable carrier.4. The pharmaceutical composition of further comprising an adjuvant.5. The pharmaceutical composition of formulated for administration to the mucosa.6. The pharmaceutical composition of formulated for intradermal claim 3 , intranasal claim 3 , intramuscular claim 3 , or subcutaneous administration.7. A method of treating or prevent tuberculosis in a mammalian subject claim 3 , the method comprising administering the pharmaceutical composition of to the subject.819-. (canceled)20. The method of wherein the pharmaceutical composition is administered to the subject's mucosa.21. The method of wherein the pharmaceutical composition is administered intradermally claim 29 , intranasally claim 29 , intramuscularly claim 29 , or subcutaneously.22. (canceled)23. The method of wherein the mammalian subject is immunocompromised.2426-. (canceled)27. The pharmaceutical composition of claim 3 , wherein the pharmaceutical composition is pyrogen free.28. The pharmaceutical composition of claim 3 , wherein the pharmaceutical composition is certified BSE-free.29. A method of inducing an immune response in a mammalian subject claim 3 , the method comprising administering a pharmaceutical composition of to the mammalian subject.30. The method of wherein the administration induces in the ...

Подробнее
Номер записи: 19
26-07-2012 дата публикации

IMPACT SENSING AND RECORDING

Номер: US20120191379A1
Автор:
Принадлежит: University of Georgia Research Foundation, Inc.

Various methods and systems are provided for impact sensing and recording. In one embodiment, an impact recording sensor includes an impulse sensing system configured to sense impacts experienced by the impact recording sensor in three dimensions and a microcontroller unit (MCU) configured to obtain impact data from the impulse sensing system and store an impact data set including the impact data in memory in response to an impact experienced by the impact recording sensor. The impact recording sensor may also include a rechargeable power source configured to supply power to the MCU. In another embodiment, an impact recording system includes and impact recording sensor and a control interface unit configured to communicatively couple with the impulse recording sensor. The control interface unit may be configured to download impact data set stored in memory of the impulse recording sensor. 1. An impact recording sensor , comprising:an impulse sensing system configured to sense impacts experienced by the impact recording sensor in three dimensions;a microcontroller unit (MCU) configured to obtain impact data from the impulse sensing system and store an impact data set including the impact data in memory in response to an impact experienced by the impact recording sensor; anda rechargeable power source configured to supply power to the MCU.2. The impact recording sensor of claim 1 , further comprising a spherical housing encasing the impulse sensing system claim 1 , the MCU claim 1 , the memory claim 1 , and the rechargeable power source.3. The impact recording sensor of claim 2 , wherein the spherical housing has a diameter of about one inch or less.4. The impact recording sensor of claim 2 , wherein the spherical housing comprises silicon rubber.5. The impact recording sensor of claim 1 , wherein the impulse sensing system comprises three single-axis accelerometers claim 1 , where two of the single-axis accelerometers are mounted on a main circuit board to sense ...

Подробнее
Номер записи: 20
02-08-2012 дата публикации

NEAR INFRARED DOPED PHOSPHORS HAVING A ZINC, GERMANIUM, GALLATE MATRIX

Номер: US20120193578A1
Автор:
Принадлежит: University of Georgia Research Foundation, Inc.

Phosphors based on transition metal-activated gallates, particularly Cr- and Ni-activated zinc germanium gallates, are disclosed herein. In some embodiments such phosphors can exhibit persistent infrared phosphorescence for as long as 400 hours. Such phosphors can be used, for example, as components of a luminescent paint. 1. A phosphor comprising a material of the formula:{'br': None, 'sub': x', 'y', 'z', '(x+(3y/2)+2z), 'ZnGaGeO:tC, mR'}wherein a portion of Ga may optionally be replaced with a Group IIIA metal;wherein a portion or all of Ge may optionally be replaced with a Group IVA metal; and{'sup': 3+', '2+, 'wherein C is Cr, Ni, or a combination thereof;'}{'sup': '+', 'R is an ion selected from a group consisting of alkaline earth ions, lanthanide ions, Li ions, and combinations thereof;'}x is 1 to 5;y is 1 to 5;z is 1 to 5;t is 0.01 to 5 and represents mol % based on the total moles of Ga and any replacements thereof; andm is 0 to 5 and represents mol % based on the total moles of Ga and any replacements thereof,wherein the phosphor has at least one emission band in the near infrared.24-. (canceled)5. The phosphor of wherein t is 0.05 to 2 and represents mol % based on the total moles of Ga and any replacements thereof.6. The phosphor of wherein m is 0 to 2 and represents mol % based on the total moles of Ga and any replacements thereof.7. The phosphor of wherein the alkaline earth ion is selected from the group consisting of Mg claim 1 , Ca claim 1 , Sr claim 1 , Ba claim 1 , and combinations thereof.8. The phosphor of wherein the lanthanide ion is selected from the group consisting of La claim 1 , Ce claim 1 , Pr claim 1 , Nd claim 1 , Eu claim 1 , Gd claim 1 , Tb claim 1 , Dy claim 1 ,Ho claim 1 , Er claim 1 , Tm claim 1 , Yb claim 1 , Lu claim 1 , and combinations thereof.9. The phosphor of wherein C is Cr.10. The phosphor of having emission band peaks at 690 to 1100 nm.11. The phosphor of wherein C is Ni.12. The phosphor of having emission band peaks at ...

Подробнее
Номер записи: 21
16-08-2012 дата публикации

Crapemyrtle plant named 'GAMAD IX'

Номер: US20120210479P1
Автор:
Принадлежит: University of Georgia Research Foundation, Inc.

A new and distinct cultivar of crapemyrtle, ‘GAMAD IX’, is provided. ‘GAMAD IX’ is a hybrid, which is characterized by intermediate growth habit, mildew resistance, and earlier flowering with abundant purple flowers. 1. A new and distinct variety of crapemyrtle plant named ‘GAMAD IX’, substantially as illustrated and described herein. ‘GAMAD IX’ is a crapemyrtle plant that is a hybrid.The new crapemyrtle plant claimed is of the variety denominated ‘GAMAD IX’.The present invention relates to the discovery of a new and distinct cultivar of the ornamental flowering shrub commonly known as crapemyrtle, and hereafter referred to by the varietal denomination ‘GAMAD IX’, as herein described and illustrated.The new crapemyrtle originated from open-pollinated seed of an unpatented seedling. ‘GAMAD IX’ was derived from plants grown at Dearing, Ga. from these seeds. The seedlings were planted in containers and selections were made for plants based on the following criteria: 1) intermediate growth habit; 2) mildew resistance; 3) early flowering; and 4) flower color and quality. ‘GAMAD IX’ was selected in 2004.Asexual reproduction by traditional vegetative cuttings since 2004 at Dearing, Ga. and in Athens, Ga. has shown that the distinguishing characteristics of this new crapemyrtle variety ‘GAMAD IX’ are stable and reproduced true-to-type in successive generations.The new crapemyrtle plant variety ‘GAMAD IX’ has not been observed under all possible environmental conditions. The phenotype may vary somewhat with variations in environment and cultural practices such as temperature and light intensity without, however, any variance in genotype.The following traits have been repeatedly observed at Dearing, Ga. and Athens, Ga., and are determined to be unique characteristics of the new crapemyrtle plant variety ‘GAMAD IX’:1. Intermediate size2. Mildew resistance3. Earlier flowering in mid-to late June (USDA Zone 7)4. Abundant purple flowersThere were no intermediate purple flowering ...

Подробнее
Номер записи: 22
13-09-2012 дата публикации

Hydrangea paniculata plant named 'PIIHP-I'

Номер: US20120233731P1
Автор: Michael Dirr
Принадлежит: Plant Introductions Inc, University of Georgia Research Foundation Inc UGARF

A new and distinct cultivar of Hydrangea paniculata plant named ‘PIIHP-I’, characterized by its compact rounded growth habit; strong stems that hold the inflorescences upright and do not splay; thick, dark green foliage; and solid inflorescences in which the showy white sepals cover the fertile flowers.

Подробнее
Номер записи: 23
04-10-2012 дата публикации

REOVIRUS COMPOSITIONS AND METHODS OF USE

Номер: US20120251564A1
Автор: Sellers Holly S.
Принадлежит: University of Georgia Research Foundation, Inc.

The present invention relates to novel strains of avian reovirus isolated from severe cases of Runting Stunting Syndrome in young broiler chickens in southeast United States. The invention is directed to avian reoviruses that impair digestion in poultry, diagnostic assays using nucleotide- or amino acid-specific components of such viruses, and to vaccines that protect chickens from disease caused by such viruses. Nucleotide sequences for the S1 gene, encoding the sigma C minor outer capsid protein, were amplified, and the nucleotide and predicted amino acid sequences were compared with sequences from other recently isolated reovirus field isolates and vaccine strains. Antigenic and molecular characterization of the newly isolated reoviruses revealed a lack of homogeneity with current U.S. isolates, with less than 60% percent amino acid similarity across the sigma C protein. Sequence comparisons with previously reported malabsorption isolates from Europe and Asia revealed a higher amino acid similarity, approaching 80%. 1. A vaccine comprising antigenic material derived from an avian reovirus , wherein said reovirus comprises an S1 protein , wherein said S1 protein comprises an amino acid sequence set forth in the group consisting of SEQ ID NOS: 2 , 4 , 6 , 8 , 10 , 12 , 14 , 16 , 18 , 20 , 22 , 24 , 26 , 28 , and 30 , and wherein said antigenic material is selected from the group consisting of live virus , live attenuated virus , inactivated virus , and one or more immunologically active subcomponents , thereof.2. The vaccine of claim 1 , wherein said reovirus comprises an S1 protein comprising the amino acid sequence set forth in SEQ ID NO: 6.3. The vaccine of further comprising one or more vaccines selected from the group consisting of infectious bronchitis virus vaccine claim 1 , Newcastle disease virus vaccine claim 1 , infectious bursal disease virus vaccine claim 1 , fowl adenovirus vaccine claim 1 , EDS virus vaccine claim 1 , and turkey rhinotracheitis virus ...

Подробнее
Номер записи: 24
18-10-2012 дата публикации

POPPET VALVE ASSEMBLY FOR CONTROLLING A PNEUMATIC ACTUATOR

Номер: US20120260993A1
Автор: Penning Bruce R.
Принадлежит: General Equipment and Manufacturing Company, Inc., d/b/a TopWorx, Inc.

A poppet valve assembly to control a pneumatic actuator may include a housing having a central bore. A first module may be disposed within the central bore, and the first module may have a first and second poppet valve. A second module may also be disposed within the central bore, and the second module may have a third and fourth poppet valve. A supply of pressurized fluid may be in fluid communication with a plurality of control valves such that pressurized fluid from the control valves opens and closes the poppet valves. The supply of pressurized fluid may also be in fluid communication with the first module and the second module such that the opening and closing of the poppet valves controls the position of the pneumatic actuator. 1. A poppet valve assembly comprising:a valve housing having a central bore;a first module disposed within the central bore, the first module comprising a first normally closed poppet valve and a second normally closed poppet valve, wherein each of the first and second normally closed poppet valves has an open position and a closed position;a central port formed in the first module, wherein the central port of the first module is adapted to be coupled to a first volume of a pneumatic cylinder;an exhaust port formed in the first module such that the central port is in fluid communication with the exhaust port when the first poppet valve is in the open position; anda supply port formed in the first module such that the central port is in fluid communication with the supply port when second poppet valve is in the open position,wherein the supply port is configured to be in fluid communication with a supply of pressurized fluid such that when the second poppet valve is in the open position, pressurized fluid is provided to the first volume of the pneumatic cylinder, andwherein the exhaust port is configured to vent pressurized fluid from the first volume of the pneumatic cylinder when the first poppet valve is in the open position.2. The ...

Подробнее
Номер записи: 25
18-10-2012 дата публикации

Compounds and Methods for Treating Mammalian Gastrointestinal Parasitic Infections

Номер: US20120264760A1
Автор: Boris Striepen, Lizbeth K. Hedstrom
Принадлежит: BRANDEIS UNIVERSITY, University of Georgia Research Foundation Inc UGARF

One aspect of the present invention relates to compounds, and pharmaceutically acceptable salts and prodrugs thereof, that are useful as inhibitors of IMPDH. The invention also provides pharmaceutical compositions comprising the compounds of the invention which selectively inhibit parasitic IMPDH. In certain embodiments, the present invention relates to selective inhibition of C. parvum inosine-5′-monophosphate-dehydrogenase over human inosine-5′-monophosphate-dehydrogenase (IMPDH type I and type II). These compounds may be used alone or in combination with other therapeutic or prophylactic agents, such as anti-virals, anti-inflammatory agents, antimicrobials and immunosuppressants.

Подробнее
Номер записи: 26
25-10-2012 дата публикации

DEVICES AND METHODS FOR FORMING NON-SPHERICAL PARTICLES

Номер: US20120267810A1
Автор: Locklin Jason, Mao Leidong, Sheppard Gareth, Zhu Taotao
Принадлежит: University of Georgia Research Foundation, Inc.

Embodiments of the present disclosure provide for devices, methods for forming non-spherical particles, and the like. 1. A device , comprising:a first fluid inlet for flowing a first liquid;a second fluid inlet for flowing a second liquid, wherein the first fluid inlet and the second fluid inlet are configured to flow the first fluid and the second fluid, respectively, into a flow chamber;a magnetic device configured to direct a magnetic force onto a first portion of the flow chamber; anda light source device configured to direct a light energy at a second portion of the flow chamber.2. The device of claim 1 , wherein the first fluid is a polymer selected from the group consisting of: photopolymers and thermal-curable polymers.3. The device of claim 1 , wherein the second fluid is a ferrofluid.4. The device of claim 1 , wherein the first portion of the flow chamber has a diameter of about 10 μm to 10 claim 1 ,000 μm and length of about 1 to 10 cm.5. The device of claim 1 , wherein the magnetic device includes at least a pair of magnets.6. The device of claim 1 , wherein the light source device is configured to direct UV light onto the second portion of the flow chamber.7. The device of claim 1 , wherein the second portion of the flow chamber is within the first portion of the flow chamber.8. The device of claim 1 , wherein the second portion of the flow chamber is at the edge of the first portion of the flow chamber at the end opposite a point where the first fluid and the second fluid are introduced to the flow chamber.9. The device of claim 1 , wherein the magnetic device is configured to control the magnetic force exerted on the first fluid to form a non-spherical shape in the second fluid.10. The device of claim 1 , wherein the light source device is configured to form a non-spherical polymer particle from the first fluid.11. A method for forming non-spherical polymer particles claim 1 , comprising:disposing a first fluid in a second fluid;causing the first ...

Подробнее
Номер записи: 27
08-11-2012 дата публикации

Pyridinone hydroxycyclopentyl carboxamides: hiv integrase inhibitors with therapeutic applications

Номер: US20120282218A1
Автор: Abdumalik A. Nishonov, Maurice O. Okello, Sanjaykumar Mishra, Vasu Nair
Принадлежит: University of Georgia Research Foundation Inc UGARF

New chiral and achiral oxy-substituted cyclopentyl pyridinone diketocarboxamides and their derivatives and methods for their preparations are disclosed. The compounds include tautomers, regioisomers and geometric isomers. These complex carboxamides are designed as inhibitors of HIV replication through inhibition of HIV integrase. The compounds are useful in the prevention or treatment of infection by HIV and in the treatment of AIDS and ARC, either as the compounds, or as pharmaceutically acceptable salts, with pharmaceutically acceptable carriers, used alone or in combination with antivirals, immunomodulators, antibiotics, vaccines, and other therapeutic agents, especially other anti-HIV compounds (including other anti-HIV integrase agents), which can be used to create combination anti-HIV cocktails. Methods of treating AIDS and ARC and methods of treating or preventing infection by HIV are also described.

Подробнее
Номер записи: 28
08-11-2012 дата публикации

Viburnum plant name 'PIIVIB-I'

Номер: US20120284887P1
Автор: Michael A. Dirr
Принадлежит: Plant Introductions Inc, University of Georgia Research Foundation Inc UGARF

A new and distinct cultivar of Viburnum plant named ‘PIIVIB-I’, characterized by its compact, mounding growth habit, small, lustrous, dark green, evergreen foliage, white flowers produced in abundance even on young plants, clusters of red fruit that turn black when mature.

Подробнее
Номер записи: 29
15-11-2012 дата публикации

GRAPHENE-COATED PYROLYTIC CARBON STRUCTURES, METHODS OF MAKING, AND METHODS OF USE THEREOF

Номер: US20120288762A1
Автор: Hardin Ian R., Zhang Ming
Принадлежит: University of Georgia Research Foundation, Inc.

Embodiments of the present disclosure provide for flexible graphene-coated pyrolytic carbon materials or structures, methods of making, methods of use, materials including the graphene-coated pyrolytic carbon material or structure, structures including the graphene-coated pyrolytic carbon material or structure, and the like.

Подробнее
Номер записи: 30
06-12-2012 дата публикации

Substrate-selective co-fermentation process

Номер: US20120308991A1
Автор: Elliot Altman, Mark Eiteman
Принадлежит: University of Georgia Research Foundation Inc UGARF

Biological method for conversion of a sugar-containing organic material into a desired biochemical product. Use of a plurality of substrate-selective cells allows different sugars in a complex mixture to be consumed concurrently and independently. The method can be readily extended to remove inhibitory compounds from hydrolysate.

Подробнее
Номер записи: 31
13-12-2012 дата публикации

DIAGNOSTIC ASSAY FOR TRYPANOSOMA CRUZI INFECTION

Номер: US20120316209A1
Автор: Etheridge, JR. Ronald D., Tarleton Rick L.
Принадлежит: University of Georgia Research Foundation, Inc.

A sensitive, multicomponent diagnostic test for infection with , the causative agent of Chagas disease, including methods of making and methods of use. Also provided is a method for screening polypeptides to identify antigenic polypeptides for inclusion as components of the diagnostic test, as well as compositions containing antigenic polypeptides. 123-. (canceled)24T. cruzi. A method for determining whether an infant has a infection , said method comprising:{'i': 'T. cruzi', 'obtaining a biological sample from an infant born to a mother known to have or suspected of having a infection, wherein said biological sample is obtained later than about 3 months after birth of the infant;'}{'i': 'T. cruzi', "contacting the infant's biological sample with a plurality of individually addressable antigenic polypeptides, or antigenic analogs or subunits thereof; and"}{'i': 'T. cruzi', 'evaluating the presence, absence, intensity or pattern of interaction of components of the biological sample with the antigenic polypeptides to determine whether the infant exhibits an antibody response that exceeds background levels.'}25. The method of further comprising:obtaining a biological sample from the infant's mother;{'i': 'T. cruzi', "contacting the mother's biological sample with the plurality of individually addressable antigenic polypeptides, or antigenic analogs or subunits, thereof; and"}{'i': T. cruzi', 'T. cruzi, "comparing the presence, absence intensity or pattern of interaction of components of the infant's biological sample with the antigenic polypeptides, to determine whether the infant's antibody response differs from the mother's antibody response, wherein a difference in antibody responses indicates that the infant may have a infection."}26. The method of wherein at least one polypeptide is selected from the polypeptides listed in Table 1 claim 24 , Table 2 or Table 4.27. The method of further comprising:obtaining an earlier biological sample from the infant shortly after ...

Подробнее
Номер записи: 32
20-12-2012 дата публикации

ALKYNES AND METHODS OF REACTING ALKYNES WITH 1,3-DIPOLE-FUNCTIONAL COMPOUNDS

Номер: US20120322974A9
Автор:
Принадлежит: University of Georgia Research Foundation, Inc.

1,3-Dipole-functional compounds (e.g., azide functional compounds) can be reacted with certain alkynes in a cyclization reaction to form heterocyclic compounds. Useful alkynes (e.g., strained, cyclic alkynes) and methods of making such alkynes are also disclosed. The reaction of 1,3-dipole-functional compounds with alkynes can be used for a wide variety of applications including the immobilization of biomolecules on a substrate. 2. The compound of wherein Rrepresents a biomolecule.3. The compound of wherein the biomolecule is selected from the group consisting of peptides claim 2 , proteins claim 2 , glycoproteins claim 2 , nucleic acids claim 2 , lipids claim 2 , saccharides claim 2 , oligosaccharides claim 2 , polysaccharides claim 2 , and combinations thereof.4. The compound of wherein each Rrepresents hydrogen.5. The compound of wherein each Rrepresents hydrogen.6. The compound of wherein Rcomprises a covalently bound organic dye.7. The compound of wherein the organic dye is a fluorescent dye.9. The compound of wherein the biotinylation product is the biotinylation product of a primary amine-containing group of the formula —(CHCHO)(CH)-L-(CHCHO)(CH)NHand/or —(CDCDO)(CD)-L-(CDCDO) claim 8 ,(CD)NH claim 8 , wherein b=0 to 100; c=0 to 100; d=0 to 100; e=0 to 100; f=0 to 100; and L is an optional cleavable linker.10. The compound of wherein the cleavable linker claim 9 , if present claim 9 , is a disulfide.12. The compound of wherein the copolymeric group comprises a hydrophilic segment and a hydrophobic segment.13. The compound of wherein the copolymeric group comprises a fragment of the formula —[CHCHO]—[C(O)(CH)O]—H claim 11 , wherein n=0 to 100 and m=0 to 100.14. A dibenzocyclooctyne having a biotin fragment attached thereto.17. A dibenzocyclooctyne having a covalently bound organic dye attached thereto.20. A dibenzocyclooctyne having a nanoparticle attached thereto.22. A method of preparing a heterocyclic compound claim 11 , the method comprising:{'claim-ref': ...

Подробнее
Номер записи: 33
27-12-2012 дата публикации

Independent Component Analysis of Surface-Enhanced Raman Scattering (SERS) Signals

Номер: US20120327407A1
Автор:
Принадлежит: University of Georgia Research Foundation, Inc.

Embodiments of the present disclosure, in one aspect, relate to methods of analyzing SERS signals, systems for analyzing SERS signals, in particular, using an independent component analysis, and the like. 1. A method of analyzing a SERS signal , comprising:acquiring SERS data from a sample,performing an independent component analysis on the SERS data, anddetermining one or more analytes present in the sample.2. The method of claim 1 , further comprising:disposing the sample on a SERS structure and generating a composition gradient.3. The method of claim 2 , wherein acquiring SERS data from the sample includes:acquiring SERS data from multiple distinct areas of the SERS structure.4. The method of claim 3 , wherein performing the independent component analysis on the SERS data comprises:comparing the SERS data obtained from the multiple distinct areas of the SERS structure.5. The method of claim 4 , further comprising:determining the ratio of one or more pairs of analysts at each of the multiple distinct areas.6. A method of analyzing a SERS signal claim 4 , comprising:disposing the sample on a SERS structure and generating a composition gradient along the x-axis, the y-axis, the diagonal axis, or a combination thereof,acquiring SERS data from a plurality of positions of the composition gradient, anddetermining the ratio of one or more pairs of analysts at each of the multiple distinct areas.7. The method of claim 6 , further comprising: determining one or more analytes present in the sample.8. The method of claim 6 , further comprising: performing an independent component analysis on the SERS data acquired from the plurality of positions along the composition gradient.9. A method of analyzing a SERS signal claim 6 , comprising:disposing the sample on a SERS structure and generating a composition gradient along the x-axis, the y-axis, the diagonal axis, or a combination thereof,acquiring SERS data from a plurality of positions of the composition gradient,performing an ...

Подробнее
Номер записи: 34
03-01-2013 дата публикации

VALVE SIGNATURE DIAGNOSIS AND LEAK TEST DEVICE

Номер: US20130000753A1
Автор: LaFountain Robert L., Li Jingli, Penning Bruce R., Rigsby Bruce
Принадлежит: General Equipment and Manufacturing Company, Inc., d/b/a TopWorx, Inc.

A valve signature diagnosis and leak testing device includes a spool valve operatively connected to a pilot valve, the pilot valve being configured to position the spool valve to one of an open position and a closed position. A blocker valve is fluidly connected to a control fluid outlet of the spool valve. An electrical module is operatively connected to the pilot valve, a supply of control fluid, and the blocker valve, the electrical module being capable of sending pulsed electrical signals to the pilot valve and the blocker valve to selectively position the spool valve and the blocker valve to an open or closed position. 1. A valve signature diagnosis and leak testing device for a control valve , the valve signature diagnosis and leak testing device comprising:a spool valve operatively connected to a pilot valve, the pilot valve being configured to position the spool valve to one of an open position and a closed position, the spool valve including a first control fluid inlet, a first control fluid outlet, and a second control fluid outlet, the first control fluid inlet being fluidly connected to a supply of control fluid and the first control fluid outlet being configured to be connected to a valve actuator;a blocker valve fluidly connected to the second control fluid outlet; andan electrical module operatively connected to the pilot valve, the supply of control fluid, and the blocker valve, the electrical module being capable of sending pulsed electrical signals to the pilot valve and the blocker valve to selectively position the spool valve and the blocker valve to an open or a closed position,wherein the open position of the spool valve fluidly connects the first control fluid inlet to the first control fluid outlet and the closed position of the spool valve fluidly connects the first control fluid outlet to the second control fluid outlet.2. The valve signature diagnosis and leak testing device of claim 1 , wherein the electrical module includes a main ...

Подробнее
Номер записи: 35
03-01-2013 дата публикации

2'-FLUORO-6'-METHYLENE CARBOCYCLIC NUCLEOSIDES AND METHODS OF TREATING VIRAL INFECTIONS

Номер: US20130005677A1
Автор:
Принадлежит: University of Georgia Research Foundation, Inc.

The present invention relates to 2′-Fluoro-6′-methylene carbocyclic nucleosides, pharmaceutical compositions containing these nucleosides and their use in the treatment or prophylaxis of a number of viral infections and secondary disease states and conditions thereof, especially including Hepatitis B virus (HBV) and secondary disease states and conditions thereof (cirrhosis and liver cancer), Heptatitis C virus (HCV), Herpes Simplex virus I and II (HSV-1 and HSV-2), cytomegalovirus (CMV), Varicella-Zoster Virus (VZV) and Epstein Barr virus (EBV) and secondary cancers which occur thereof (lymphoma, nasopharyngeal cancer, including drug resistant (especially including lamivudine and/or adefovir resistant) and other mutant forms of these viruses. 2. The compound according to claim 1 , wherein Ris H.3. The compound according to wherein Rand Rare each independently H or a C-Cacyl group.4. The compound according wherein R claim 1 , Rand Rare each H.8. The compound according to wherein R claim 6 , Rand Rare each independently H or a C-Cacyl group.9. The compound according to wherein R is H or F.10. The compound according to claim 1 , wherein Ris H and Rand Rare each independently H or a C-Cacyl group.11. The compound according to wherein Ris an acyl group claim 1 , a phosphate claim 1 , phosphodiester or phosphoramidate group.16. A pharmaceutical composition comprising an effective amount of a compound according to claim 1 , optionally in combination with a pharmaceutically acceptable carrier claim 1 , additive or excipient.17. The pharmaceutical composition according to comprising an effective amount of an additional antiviral agent.18. (canceled)19. (canceled)20. (canceled)21. (canceled)22. A composition according to further in combination with at least one anticancer agent.23. The composition according to wherein said anticancer agent is selected from the group consisting of oxaliplatin claim 22 , 5-fluorouracil claim 22 , gemcitabine or mixtures thereof.24. (canceled) ...

Подробнее
Номер записи: 36
24-01-2013 дата публикации

WIRELESS MONITORING AND CONTROL OF SAFETY STATIONS IN A PROCESS PLANT

Номер: US20130021167A1
Автор: Harper, JR. Ronald D.
Принадлежит: General Equipment and Manufacturing Company, Inc., d/b/a TopWorx, Inc.

A safety station for use in a process plant includes one or more leverless limit switches to detect activation of one or more parts of the safety station. The safety station further includes a wireless transmitter coupled to the leverless limit switches to transmit signals associated with the safety station to a base station device, which is communicatively coupled to one or more control and/or monitoring devices. 1. A safety station for use in a process plant , the safety station comprising:one or more leverless limit switches to detect activation of one or more parts of the safety station; anda wireless transmitter coupled to the leverless limit switches to transmit signals associated with the safety station to a base station device, wherein the base station device is communicatively coupled to one or more control and/or monitoring modules.2. The safety station of claim 1 , wherein the leverless limit switch is a GO® switch manufactured by the TopWorx corporation.3. The safety station of claim 1 , wherein the leverless limit switch remains latched until physically reset.4702. The safety station of claim 1 , wherein the wireless transmitter is the Rosemount dual input transmitter manufactured by the Emerson corporation.5. The safety station of claim 1 , wherein the wireless transmitter is an intrinsically safe wireless transmitter.6. The safety station of claim 1 , wherein the safety station is a safety shower and/or an eye wash station.7. The safety station of claim 1 , wherein at least one of the one or more control and/or monitoring stations is a remote touch screen panel.8. The safety station of claim 1 , wherein at least one of the one or more control and/or monitoring stations is a paperless recorder.9. The safety station of claim 1 , wherein at least one of the one or more control and/or monitoring stations is a workstation.10. A safety station monitoring and control system in a process plant claim 1 , the system comprising:one or more safety stations ...

Подробнее
Номер записи: 37
31-01-2013 дата публикации

SWITCH MODULE

Номер: US20130027831A1
Автор: Penning Bruce R.
Принадлежит: General Equipment and Manufacturing Company, Inc., d/b/a TopWorx, Inc.

A switch module used for position sensing may be operated in a number of modes for compatibility with a number of legacy position sensing products. A dry switch circuit can be configured to provide a direct output, emulating dry reed, high-side or low-side switched configurations. Alternatively, the dry switch circuit can be connected to an input of a NAMUR circuit to provide the known current output for that standard. In another configuration the dry switch can be selectively coupled to one of two NAMUR circuits allowing the switch module to provide a low-to-high current NAMUR output or a high-to-low current NAMUR output. 1. A switch module arranged and adapted to report a position of a moveable element external to the switch module , the switch module comprising:a first external connection, a second external connection, and a third external connection;a dry contact relay having a relay contact position responsive to a position of a component external to the switch module, the dry contact relay having a common connection, a normally open connection and a normally closed connection, where the normally open connection corresponds to a first position of the moveable element and the normally closed connection corresponding to a second position of the moveable;a NAMUR circuit having a first input connection pair and a first output connection pair;an electrical connection from the normally open connection of the dry relay to a first input of the first input connection pair of the NAMUR circuit;a selector operable to connect the common connection of the dry contact relay to i) a null contact of the selector or ii) a second input of the first input connection pair of the NAMUR circuit;a second electrical connection from the first output of the NAMUR circuit to one of the first external connection or the second external connection; anda third electrical connection between the second output of the NAMUR circuit to the third external connection;a first jumper that removeably ...

Подробнее
Номер записи: 38
31-01-2013 дата публикации

PLANT ARTIFICIAL CHROMOSOMES AND METHODS OF MAKING THE SAME

Номер: US20130031671A1
Автор: Dawe R. Kelly
Принадлежит: University of Georgia Research Foundation, Inc.

An engineered centromere, and systems and methods of using the engineered centromere are described. The engineered centromere can have tandem repeats of a DNA sequence with binding motifs to permit binding of fusion proteins that include a DNA binding protein and a kinetochore protein to activate the engineered centromere. Also described are a plant artificial chromosome that includes the engineered centromere, a transgenic plant containing the engineered chromosome, and a method of synthesizing a large molecule by adding multiple genes using the plant artificial chromosome. 1. An engineered centromere comprising tandem repeats of a DNA sequence , comprising:one or more binding motifs for one or more DNA binding proteins, wherein the one or more binding motifs permit binding of one or more fusion proteins comprising the DNA binding protein and a kinetochore protein to activate the engineered centromere.2. The engineered centromere of claim 1 , wherein the fusion protein further comprises a nuclear localization signal.3. The engineered centromere of claim 2 , wherein the nuclear localization signal is the nuclear localization signal to PKKRKV.4. The engineered centromere of claim 1 , wherein the fusion protein further comprises an eptitope recognition sequence.5. The engineered centromere of claim 4 , wherein the epitope recognition sequence comprises multimers of the HA epitope tag YPYDVPDYA.6. The engineered centromere of claim 1 , wherein the one or more DNA binding motifs is selected from the group consisting of TetR (SEQ ID NO. 1) claim 1 , CENP-B box (SEQ ID NO. 2) claim 1 , LacO (SEQ ID NO. 3) claim 1 , LexA (SEQ ID NO. 4) claim 1 , Gal4 (SEQ ID NO. 5) claim 1 , and combinations thereof7. The engineered centromere of claim 1 , wherein the DNA sequence is SEQ ID NO. 6.8. The engineered centromere of claim 1 , comprising at least 500 tandem repeats.9. The engineered centromere of claim 1 , comprising at least 1000 tandem repeats.10. The engineered centromere of ...

Подробнее
Номер записи: 39
14-02-2013 дата публикации

BIOLOGICAL OPTIMIZATION SYSTEMS FOR ENHANCING PHOTOSYNTHETIC EFFICIENCY AND METHODS OF USE15

Номер: US20130040380A1
Автор: Chinnasamy Senthil, Das Keshav C., Hunt Ryan, Rolim de Mattos Erico
Принадлежит: University of Georgia Research Foundation, Inc.

The present disclosure relates to biological optimization systems for enhancing photosynthetic efficiency and methods of use. 18-. (canceled)9. A biological optimization system for enhancing photosynthetic efficiency of a photosynthetic organism comprising:a source of pulsed light; anda chlorophyll fluorometer.10. The biological optimization system of claim 9 , wherein the photosynthetic organism comprises a plant or animal utilizing chlorophyll as an energy collector/converter.11. The biological optimization system of claim 10 , wherein the photosynthetic organism is selected from the group consisting of: microalgae claim 10 , macroalgae claim 10 , terrestrial plant claim 10 , coral claim 10 , corallimorph claim 10 , anemone claim 10 , clam claim 10 , a host organism containing a photosynthetic symbiotic organism claim 10 , and a combination thereof.12Chlorella sorokiniana, Chlorella minutissima,. The biological optimization system of claim 11 , wherein the microalgae is selected from the group consisting of: and a combination thereof.13. The biological optimization system of claim 9 , wherein the source of pulsed light is a LED illuminating system.14. The biological optimization system of claim 9 , wherein the chlorophyll fluorometer provides chlorophyll fluorescence feedback to a chlorophyll fluorescence feedback control system claim 9 , wherein the chlorophyll fluorescence feedback control system adjusts the output of the source of pulsed light.15. The biological optimization system of claim 14 , wherein the chlorophyll fluorescence feedback includes one or more of the following: photosynthetic efficiency claim 14 , photochemical processing (qP) claim 14 , or waste heat dissipation (NPQ or qN) claim 14 , of the photosystem.16. The biological optimization system of claim 14 , wherein the chlorophyll fluorescence feedback is utilized adjust one or more of the following: a pulse rate claim 14 , pulse on/off duration claim 14 , light intensity claim 14 , or light ...

Подробнее
Номер записи: 40
14-02-2013 дата публикации

Method And System Using Computer Simulation For The Quantitative Analysis Of Glycan Biosynthesis

Номер: US20130041592A1
Автор: Han Jun, KOCHUT Krzysztof J., MILLER JOHN A., WELLS Lance, YORK William S.
Принадлежит: University of Georgia Research Foundation, Inc.

This invention provides a quantitative analysis of glycan biosynthesis along meta pathways using computer simulation for comparing a computer generated spectrum to experimental data to quantitatively track the biosynthesis. Computer simulating the mass spectra of isotopic detection of aminosugars with glutamine experiments allows modeling the glycan biosynthesis over time, via changes in the N and N isotope abundance levels, to estimate the relative abundance of molecules involved in glycan biosynthesis, from experimental mass spectra. Gradient search optimization is used to maximize the coefficient of determination between the experimental spectrum and the simulated spectrum. These relative abundances are then fed into a pathway simulation model to analyze glycan biosynthesis. Simulating a mass spectrum allows reconfirming the identification, quantifying the isotopic configurations and obtaining the relative abundance of each as samples are taken at periodic intervals, which is then organized to allow tracking the changes in abundance levels over time. 1. A method for quantitatively tracking glycan biosynthesis comprising:growing a target biological material in the presence of an isotope labeled glutamine, the biological material thereby producing labeled glycans;preparing a plurality of parameterized spectral patterns of glycans using a computer simulation program by calculating simulated spectral signatures for every isotope analog thereof;performing a spectral analysis of each isotope analog and obtaining actual spectral patterns therefrom;comparing the actual spectral patterns to the simulated spectral patterns and adjusting the simulated spectra for improving the accuracy thereof;using labeled glutamine and performing a biosynthesis to produce labeled glycans;obtaining a sample and spectrally analyzing the sample at predetermined time intervals during the biosynthesis of the labeled glycans; and,comparing the sample spectra to the computer simulated spectra ...

Подробнее
Номер записи: 41
21-02-2013 дата публикации

MICROBIAL PRODUCTION OF PYRUVATE AND OTHER METABILITES

Номер: US20130045512A1
Автор: Altman Elliot, Eiteman Mark A., Zhu Yihui
Принадлежит: University of Georgia Research Foundation, Inc.

Microbial production of pyruvate and metabolites derived from pyruvate in cells exhibiting reduced pyruvate dehydrogenase activity compared to wild-type cells. Acetate and glucose are supplied as a carbon sources. 1. A bacterial cell for use in making a metabolite comprising pyruvate or a pyruvate derivative , the bacterial cell exhibiting reduced activity of at least one enzyme in the pyruvate dehydrogenase (PDH) complex of enzymes , compared to a wild-type bacterial cell; wherein the bacterial cell is capable of accumulating the metabolite to a concentration of at least about 3.3 g/L when cultured in the presence of glucose and at least one of acetate and ethanol.2E. coli. The bacterial cell of which is an cell.3. The bacterial cell of further exhibiting added or increased NADH oxidase activity compared to a wild-type bacterial cell.4. The bacterial cell of further exhibiting reduced activity of at least one of phosphoenolpyruvate carboxylase (PEP carboxylase) and pyruvate oxidase compared to a wild-type bacterial cell.5. The bacterial cell of further exhibiting reduced activity of at least one of phosphoenolpyruvate synthase and pyruvate formate lyase claim 1 , compared to a wild-type bacterial cell.6. The bacterial cell of further exhibiting added or increased alanine dehydrogenase activity compared to a wild-type bacterial cell.7. The bacterial cell of further exhibiting reduced lactate dehydrogenase activity.8. The bacterial cell of further exhibiting an increase in the amount of NAD claim 1 , or the rate at which NAD is regenerated claim 1 , compared to a wild-type bacterial cell.9. The bacterial cell of wherein pyruvate dehydrogenase (PDH) activity is undetectable.10. The bacterial cell of wherein a gene encoding at least one enzyme in the pyruvate dehydrogenase (PDH) complex of enzymes is knocked out.12. The method of wherein the primary carbon source comprises glucose or glycerol.13. The method of wherein the primary carbon source comprises glucose and ...

Подробнее
Номер записи: 42
21-03-2013 дата публикации

TYROSINE KINASE INHIBITORS AS ANTI-KINETOPLASTID AND ANTI-APICOMPLEXAN AGENTS

Номер: US20130072484A1
Автор: Mensa-Wilmot Kojo
Принадлежит: University of Georgia Research Foundation, Inc.

The present invention provides methods of killing, inhibiting the growth, and/or inhibiting the reproduction of kinetoplastid or apicomplexan protozoan with tyrosine kinase inhibitors. 129-. (canceled)30. A composition for treating or preventing a kinetoplastid protozoan infection in a subject , the composition comprising an effective amount of one or more tyrosine kinase inhibitors and an effective amount of one or more conventional anti-kinetoplastid therapeutic agent , wherein the conventional anti-kinetoplastid therapeutic agent is not a tyrosine kinase inhibitor.31Trypanosoma,Trypanosoma. A method of killing and/or inhibiting the growth of the bloodstream form of a kinetoplastid protozoan of the genus the method comprising contacting the bloodstream form of the kinetoplastid protozoan of the genus with a tyrosine kinase inhibitor , wherein the tyrosine kinase inhibitor is a 4-anilinoquinazoline or tyrphostin.32Trypanosoma. A method of killing and/or inhibiting the growth of the blood stream form of a kinetoplastid protozoan of the genus in a subject , the method comprising administering to the subject an effective amount of a tyrosine kinase inhibitor; wherein the tyrosine kinase inhibitor is a 4-anilinoquinazoline or tyrphostin.33T. cruzi, T. brucei, T.b. gambiense,T.b. rhodesiense.. The method of claim 31 , wherein the kinetoplastid protozoan is selected from the group consisting of and34T. cruzi, T. brucei, T.b. gambiense,T.b. rhodesiense.. The method of claim 32 , wherein the kinetoplastid protozoan is selected from the group consisting of and35. The method of claim 31 , wherein the tyrosine kinase inhibitor is selected from the group consisting of AG1478 claim 31 , A47 claim 31 , sunitinib claim 31 , erlotinib claim 31 , imatinib claim 31 , sorafenib claim 31 , lapatinib claim 31 , and gefitinib.36. The method of claim 32 , wherein the tyrosine kinase inhibitor is selected from the group consisting of AG1478 claim 32 , A47 claim 32 , sunitinib claim 32 , ...

Подробнее
Номер записи: 43
28-03-2013 дата публикации

ACTIVATORS OF INNATE IMMUNITY

Номер: US20130078281A1
Автор: He Biao, Luthra Priya
Принадлежит: University of Georgia Research Foundation, Inc.

The present invention includes IFNS activating agents that activate expression of IFN-β, activate NF-κB expression, activate an innate immune response, activate the expression of one or more cytokines, and/or induce the expression of interferon beta (IFN-β) through a RNase L and/or MDA5-dependent pathway. Such IFNS activating agents include single stranded RNAs that encode for conserved region II of the L protein of a negative stranded RNA virus, including, but not limited to, viruses of the family Paramyxoviridae. Also included are methods of making and using such IFNS activating agents and compositions and kits including such IFNS activating agents. 1. A method of activating interferon beta expression in a subject and/or activating NF-κB expression in a subject , the method comprising delivering an isolated single stranded RNA sequence , the isolated single stranded RNA sequence comprising a nucleotide sequence that is at least about 90% identical to a nucleotide sequence encoding conserved region II of the L protein of a negative stranded RNA virus , or a fragment thereof , to the subject.2. The method of wherein the isolated single stranded RNA sequence comprises a nucleotide sequence that is at least about 90% identical to the nucleotide sequence SEQ ID NO:1 claim 1 , or a fragment thereof.3. A method of treating a viral disease claim 1 , cancer claim 1 , and/or an autoimmune disease in a subject claim 1 , the method comprising delivering an isolated single stranded RNA sequence to the subject claim 1 , the isolated single stranded RNA sequence comprising a nucleotide sequence that is at least about 90% identical to a nucleotide sequence encoding conserved region II of the L protein of a negative stranded RNA virus claim 1 , or a fragment thereof claim 1 , wherein the isolated single stranded RNA sequence activates the expression of interferon beta and/or NF-κB in the subject.4. The method of claim 3 , wherein the isolated single stranded RNA sequence comprises ...

Подробнее
Номер записи: 44
28-03-2013 дата публикации

Sorghum Grain Shattering Gene and Uses Thereof in Altering Seed Dispersal

Номер: US20130081158A1
Автор: Paterson Andrew, Tang Haibao
Принадлежит: University of Georgia Research Foundation, Inc.

Compositions and methods relating to identification of the sorghum grain shattering gene (Sh1) for use in modulating fruit dehiscence in a plant are provided. For example, methods are provided for developing genetically modified plant varieties in which the natural seed dispersal process is delayed. Likewise, methods are provided for treating a plant in order to delay fruit dehiscence in the plant. Screening methods are also provided for identifying chemical agents that can modify natural seed dispersal. 1. An isolated nucleic acid comprising a nucleic acid sequence selected from the group consisting of (1) a nucleic acid sequence at least 90% identical to SEQ ID NO:1 , 2 , 3 , 4 , 5 , 6 , or a complement thereof (2) a nucleic acid sequence of a polynucleotide that hybridizes under stringent conditions to a polynucleotide consisting of the nucleic acid sequence SEQ ID NO:1 , 2 , 3 , 4 , 5 , 6 , or complement thereof (3) a nucleic acid sequence encoding SEQ ID NO: 12 , 13 , 14 , or 15 , or a complement thereof and (4) a nucleic acid sequence of a polynucleotide that hybridizes under stringent conditions to a polynucleotide encoding SEQ ID NO: 12 , 13 , 14 , or 15 , or a complement thereof.2. A recombinant expression vector comprising the isolated nucleic acid of operably linked to an expression control sequence.3. The recombinant expression vector of claim 2 , wherein the expression control sequence is a heterologous expression control sequence.4. The recombinant expression vector of claim 3 , wherein the expression control sequence comprises a constitutive promoter.5. The recombinant expression vector of claim 3 , wherein the expression control sequence comprises a tissue specific promoter.6. A isolated polypeptide comprising an amino acid sequence of SEQ ID NO:12 claim 3 , 13 claim 3 , 14 claim 3 , or 15 claim 3 , or variant thereof comprising at least 90% sequence identity to SEQ ID NO: 12 claim 3 , 13 claim 3 , 14 claim 3 , or 15.7. A transgenic plant or ...

Подробнее
Номер записи: 45
25-04-2013 дата публикации

PLANTS WITH ALTERED CELL WALL BIOSYNTHESIS AND METHODS OF USE

Номер: US20130102022A1
Автор: Adams Michael W.W., Biswal Ajaya Kumar, Gelineo-Albersheim Ivana, Hao Zhangying, Hunt Kimberly D., KATAEVA Irina, Mohnen Debra A.
Принадлежит: University of Georgia Research Foundation, Inc.

Provided herein are plants having altered expression of a GAUT polypeptide. Such plants have phenotypes that may include decreased recalcitrance, increased growth, decreased lignin content, or a combination thereof. Also provided herein are methods of making and using such plants. 1. A method for using a transgenic plant , the method comprising processing a transgenic plant to result in pulp , wherein the transgenic plant comprises decreased expression of a coding region encoding a GAUT polypeptide compared to a control plant.2. The method of wherein the processing comprises a physical pretreatment claim 2 , a chemical pretreatment claim 2 , or a combination thereof.3. The method of further comprising hydrolyzing the processed pulp.4. The method of further comprising contacting the processed pulp with an ethanologenic microbe.5. The method of wherein the ethanologenic microbe is a eukaryote.6. The method of further comprising obtaining a metabolic product.7. The method of wherein the metabolic product comprises ethanol.8. The pulp of .9. A method comprising hydrolyzing a pulp claim 1 , wherein the pulp comprises cells of a transgenic plant claim 1 , wherein the cells comprise a mutation in a coding region encoding a GAUT polypeptide.10. The method of wherein the hydrolyzing comprises contacting the pulp with a composition comprising a cellulase under conditions suitable for hydrolysis.11. The method of further comprising contacting the hydrolyzed pulp with an ethanologenic microbe.12. The method of wherein the ethanologenic microbe is a eukaryote.13. The method of further comprising obtaining a metabolic product.14. The method of wherein the metabolic product comprises ethanol.15. A method for producing a metabolic product comprising:contacting under conditions suitable for the production of a metabolic product a microbe with a composition comprising a pulp obtained from a transgenic plant, wherein the transgenic plant comprises decreased expression of a coding ...

Подробнее
Номер записи: 46
16-05-2013 дата публикации

Alpha-tubulin acetyltransferase

Номер: US20130121989A1
Автор: Dorota Wloga, Jacek Gaertig, Shilpa Akella
Принадлежит: University of Georgia Research Foundation Inc UGARF

Polypeptides with tubulin acetyltransferase activity are described, as are nucleic acids encoding said polypeptides, and methods of use. The invention further provides enhancers and inhibitors of tubulin acetyltransferase activity, as well as cells having altered tubulin transferase activity.

Подробнее
Номер записи: 47
23-05-2013 дата публикации

THIN LAYER CHROMATOGRAPHY-SURFACED ENHANCED RAMAN SPECTROSCOPY CHIPS AND METHODS OF USE

Номер: US20130128265A1
Автор: Abell Justin L., Chen Jing, Zhao Yiping
Принадлежит: University of Georgia Research Foundation, Inc.

The present disclosure includes methods of simultaneous analyte separation and detection using surface enhanced Raman spectroscopy (SERS)-active ultra thin layer chromatography (UTLC) chips. The SERS-active UTLC chips of the present disclosure are used to physically separate compounds within a mixture, which are then identified based on their unique SERS spectra. 1. A method of simultaneous analyte separation and detection in a sample , comprising:providing a SERS-active UTLC chip, wherein the SERS-active UTLC chip comprises an array of nanostructures on a surface of a substrate;applying at least one sample comprising at least one analyte to the SERS-active UTLC chip;acquiring at least one SERS spectra for each sample at the sample origin on the chip;immersing at least a portion of the SERS-active UTLC chip in a mobile phase solvent, wherein the at least one sample is above the mobile phase solvent;developing the chip so that the at least one analyte is physically separated;acquiring at least one SERS spectra for each sample along an UTLC development direction; andanalyzing all of the SERS spectra to identify the at least one analyte in each sample.2. The method of claim 1 , wherein the array of nanostructures comprise Ag nanorods fabricated by oblique angle deposition (OAD).3. The method of claim 2 , wherein a tilt angle β between an individual nanorod and the substrate surface is less than about 90 degrees4. The method of claim 3 , wherein the OAD fabrication comprises:rotating the substrate in a polar direction relative to a vapor arrival line of a vapor flux of a material to achieve a desired incident angle between the vapor arrival line and the substrate;optionally rotating the substrate azimuthally;exposing at least a portion of the surface of the substrate to the vapor flux of a material at the desired incident angle; andforming the array of nanorods on the surface of the substrate.5. The method of claim 4 , wherein the substrate is planar claim 4 , wherein ...

Подробнее
Номер записи: 48
23-05-2013 дата публикации

MODIFIED INFECTIOUS LARYNGOTRACHEITIS VIRUS (ILTV) AND USES THEREOF

Номер: US20130129780A1
Автор: Garcia Maricarmen, Mundt Alice, Mundt Egbert
Принадлежит: University of Georgia Research Foundation, Inc.

Provided herein are modified infectious largotracheitis viruses (ILTVs) and methods of using the same. For example, provided are attenuated ILTVs. The attenuated ILTVs can be used to illicit immune responses in avian species. Optionally, the attenuated ILTVs can be used to vaccinate an avian subject or a population of avian subjects. Optionally, an attenuated ILTV is administered in ovo to an avian egg. One or more such in ovo administration can be used to increase the immunity of an avian herd. 1. A composition comprising an attenuated infectious laryngotracheitis virus (ILTV) comprising a glycoprotein J mutation , wherein the mutation inhibits expression of glycoprotein J.2. The composition of claim 1 , wherein the attenuated ILTV comprises USDA challenge strain USDA-ch.3. The composition of claim 1 , wherein the mutation inhibits the expression of glycoprotein J protein.4. The composition of claim 3 , wherein the mutation comprises a glycoprotein J promoter element mutation and wherein the mutation inhibits a function of the promoter element.5. The composition of claim 1 , wherein the mutation comprises a deletion of a glycoprotein J nucleotide sequence.6. The composition of claim 5 , wherein the mutation comprises a complete or partial deletion of SEQ ID NO:1.7. The composition of claim 6 , wherein the mutation comprises a deletion of nucleotides 1-2291 of SEQ ID NO:1.8. The composition of claim 6 , wherein a reporter protein expression cassette is inserted at the point of the deletion.9. The composition of claim 8 , wherein the reporter protein is green-fluorescent protein.10. The composition of claim 6 , wherein the mutation comprises a deletion of nucleotides 1-2188 of SEQ ID NO:1.11. The composition of claim 10 , wherein a reporter protein expression cassette is inserted at the point of the deletion.12. The composition of claim 11 , wherein the reporter protein is green-fluorescent protein.13. The composition of claim 10 , wherein a viral protein expression ...

Подробнее
Номер записи: 49
25-07-2013 дата публикации

Biocidal iron oxide coating, methods of making, and methods of use

Номер: US20130189375A1
Автор: Pradip Basnet, Ravirajsinh Jadeja, Yen-Con Hung, Yiping Zhao
Принадлежит: University of Georgia Research Foundation Inc UGARF

Embodiments of the present disclosure include visible light antimicrobial materials comprising α-Fe 2 O 3 nanostructures fabricated by electron beam evaporation, methods of making the antimicrobial materials, and methods of using the antimicrobial materials.

Подробнее
Номер записи: 50
01-08-2013 дата публикации

VACCINE DELIVERY METHOD

Номер: US20130195910A1
Автор: HARN DONALD A., MCEWEN LISA, QUEIROZ RAFAELLA
Принадлежит: University of Georgia Research Foundation, Inc.

The present invention includes a composition including as one component a slurry matrix that is a liquid at room temperature and a gel at physiological pH, physiological salt concentrations and/or physiological temperatures and as a second component one or more antigens. Also include are methods of inducing an immune response in a subject and vaccinating a subject by administering such compositions. 1. A composition comprising as one component a slurry matrix that is a liquid at room temperature and a gel at physiological pH , physiological salt concentrations and/or physiological temperatures and as another component one or more antigens.2. The composition of claim 1 , wherein the slurry matrix comprises a peptide hydrogel claim 1 , or a derivative thereof.3. The composition of claim 1 , wherein the slurry matrix comprises a peptide hydrogel of the peptide scaffold RADARADARADARADA claim 1 , or a derivative thereof.4. The composition of claim 3 , wherein the peptide hydrogel comprises PURAMATRIX claim 3 , or a derivative thereof.5. The composition of claim 1 , wherein the slurry matrix comprises MATRIGEL claim 1 , or a derivative thereof.6. The composition of further comprising one of more adjuvants.7. The composition of claim 1 , further comprising a Toll-Like Receptor (TLR) agonist and/or a cytokine8. The composition of claim 7 , wherein the TLR agonist comprises a TLR4 and/or TLR9 agonist.9. The composition of claim 8 , wherein the TLR9 agonist comprises a CpG oligodeoxynucleotide (ODN).10burkholderia. The composition of claim 1 , wherein the antigen comprises a hepatitis antigen claim 1 , an influenza antigen claim 1 , a schistosomiasis antigen claim 1 , and/or a antigen claim 1 , or an antigenic fragment thereof.11. A method of producing an immune response in a subject claim 1 , the method comprising administering a composition of to the subject.12. A method of delivering one or more immunogenic antigens to a subject claim 1 , the method comprising ...

Подробнее
Номер записи: 51
29-08-2013 дата публикации

Spiro[2.4]heptanes for Treatment of Flaviviridae Infections

Номер: US20130224152A1
Автор: Chu Chung K.
Принадлежит: University of Georgia Research Foundation, Inc.

Compounds, methods, and compositions for the treatment of infections in or exposure to humans and other host animals of Flaviviridae viruses, including HCV, that includes the administration of an effective amount of a spiro[2.4]heptane as described herein or a pharmaceutically acceptable salt or prodrug thereof, optionally in a pharmaceutically acceptable carrier, are provided. The spiro[2.4]heptane compounds either possess antiviral activity, or are metabolized to a compound that exhibits such activity. 3. The spiro[2.4]heptane of claim 1 , wherein the natural or non-natural heteroaryl or heterocyclic moiety is a pyrimidine or purine.4. The spiro[2.4]heptane of claim 3 , wherein the purine or pyrimidine is selected from the group consisting of cytosine claim 3 , 5-halocytosine claim 3 , uracil claim 3 , 5-halouracil claim 3 , 5-methylcytosine claim 3 , thymine claim 3 , adenine claim 3 , thymine claim 3 , guanine claim 3 , xanthine claim 3 , or hypoxanthine.5. The spiro[2.4]heptane of claim 4 , wherein the pyrimidine is 5-fluorocytosine or 5-fluorouracil.6. The spiro[2.4]heptane of claim 4 , wherein the pyrimidine is uracil.7. The spiro[2.4]heptane of claim 4 , wherein the pyrimidine is cytosine.8. The spiro[2.4]heptane of claim 1 , wherein Ris a phosphoramidate.9. The spiro[2.4]heptane of claim 1 , wherein Ris methyl claim 1 , Ris F or OR claim 1 , and Ris OR.10. The spiro[2.4]heptane of claim 9 , wherein Ris uracil.11. The spiro[2.4]heptane of claim 10 , wherein Ris phosphoramidate.12. The spiro[2.4]heptane of claim 2 , wherein B is a pyrimidine.13. The spiro[2.4]heptane of claim 12 , wherein the pyrimidine is selected from the group consisting of cytosine claim 12 , 5-halocytosine claim 12 , uracil claim 12 , 5-halouracil claim 12 , 5-methylcytosine claim 12 , thymine claim 12 , adenine claim 12 , guanine claim 12 , xanthine claim 12 , or hypoxanthine.14. The spiro[2.4]heptane of claim 12 , wherein the pyrimidine is 5-fluorocytosine or 5-fluorouracil or 5- ...

Подробнее
Номер записи: 52
19-09-2013 дата публикации

Algal Floway (AGF) System for Economical and Efficient Harvesting of Algal Biomass and Method of Use

Номер: US20130244309A1
Автор: Das Keshav C., Singh Manjinder
Принадлежит: University of Georgia Research Foundation, Inc.

The present disclosure includes algal floway (AGF) systems for continuous, specific, economical, and efficient harvesting of algae biomass. 1. An algal floway (AGF) system comprising: a tub, wherein the tub comprises a first sink on a first end of the tub, a second sink on an opposite end of the tub, and a horizontal surface between the first sink and the second sink, wherein the first sink comprises at least one opening on a base of the first sink for feeding algae culture from an algal cultivation reactor to the algal floway and wherein the second sink comprises at least one opening on a base of the second sink for draining algae culture from the algal floway to the algal cultivation reactor;', 'a substrate on the horizontal surface of the tub; and', 'at least one membrane on a surface of the substrate, wherein the at least one membrane supports the attachment and entrapment of algae; and, 'an algal floway structure, wherein the algal floway structure comprisesa pump, wherein the pump circulates algae culture from the algae cultivation reactor through the AGF floway structure.2. The AGF system of claim 1 , further comprising an algal cultivation reactor claim 1 , wherein the algal cultivation reactor comprises a raceway.3. The AGF system of claim 1 , wherein the at least on membrane comprises a first membrane and a second membrane claim 1 , wherein the first membrane comprises a geotextile fabric claim 1 , and wherein the second membrane comprises at least one screen.4. The AGF system of claim 3 , wherein the substrate comprises an about 0.5 to 1.0 inch thick plastic sheet claim 3 , and wherein the substrate claim 3 , the first membrane claim 3 , and the second membrane comprise a three layered sandwich structure on the horizontal surface of the tub.5. The AGF system of claim 1 , wherein the algal floway structure is inclined at an angle of 0.1 to about 15 degrees.6. The AGF system of claim 3 , wherein the screen is selected from the group consisting of: a metal ...

Подробнее
Номер записи: 53
17-10-2013 дата публикации

Systems And Methods For Measuring Mitochondrial Capacity

Номер: US20130274573A1
Автор: McCully Kevin K., Ryan Terence E.
Принадлежит: University of Georgia Research Foundation, Inc.

In one embodiment, measuring mitochondrial capacity includes performing arterial occlusions on a patient, measuring oxygenated hemoglobin/myoglobin and deoxygenated hemoglobin/myoglobin within the patient's body during the occlusions, calculating a blood volume correction factor that accounts for a change in blood volume that occurs during the arterial occlusions, and applying the correction factor to the measured oxygenated hemoglobin/myoglobin and deoxygenated hemoglobin/myoglobin measurements to obtain correct oxygenated hemoglobin/myoglobin and deoxygenated hemoglobin/myoglobin measurements. 1. A method for measuring mitochondrial capacity , the method comprising:performing arterial occlusions on a patient;measuring oxygenated hemoglobin/myoglobin and deoxygenated hemoglobin/myoglobin within the patient's body during the occlusions;calculating a blood volume correction factor that accounts for a change in blood volume that occurs during the arterial occlusions; andapplying the correction factor to the measured oxygenated hemoglobin/myoglobin and deoxygenated hemoglobin/myoglobin measurements to obtain corrected oxygenated hemoglobin/myoglobin and deoxygenated hemoglobin/myoglobin measurements.2. The method of claim 1 , wherein performing arterial occlusions comprises applying a blood pressure cuff to a limb of the patient.3. The method of claim 1 , wherein measuring oxygenated hemoglobin/myoglobin and deoxygenated hemoglobin/myoglobin comprises obtaining oxygenated hemoglobin/myoglobin and deoxygenated hemoglobin/myoglobin signals using a near-infrared spectroscopy (NIRS) device.4. The method of claim 3 , wherein calculating a blood volume correction factor comprises calculating a correction factor that adjusts the measured oxygenated hemoglobin/myoglobin and deoxygenated hemoglobin/myoglobin signals so that a decrease in the oxygenated hemoglobin/myoglobin signal is equivalent to an increase in the deoxygenated hemoglobin/myoglobin signal.7. The method of claim ...

Подробнее
Номер записи: 54
24-10-2013 дата публикации

METHODS FOR LABELING A SUBSTRATE HAVING A PLURALITY OF THIOL GROUPS ATTACHED THERETO

Номер: US20130281656A1
Автор: Arumugam Selvanathan, POPIK VLADIMIR
Принадлежит: University of Georgia Research Foundation, Inc. Boyd Graduate Studies Research Center

Methods for derivatizing the surface of a substrate having a plurality of thiol groups thereon are disclosed herein. The method can include reacting the thiol groups with an o-quinone methide, which can optionally be generated by irradiating an o-quinone methide precursor compound. In some embodiments, the method can advantageously be reversible. Exemplary o-quinone methides having a cyclic alkyne attached thereto, and precursor compounds for generating such compounds, are also disclosed herein. 3. The method of wherein the substrate comprises a planar surface or a bead.4. The method of wherein the substrate is selected from the group consisting of glass claim 1 , quartz claim 1 , silica claim 1 , a metal claim 1 , a semi-conductor claim 1 , a polymer claim 1 , a membrane claim 1 , a liposome claim 1 , a micelle claim 1 , a macromolecule claim 1 , a biomaterial claim 1 , and combinations thereof.5. The method of wherein the biomaterial is selected from the group consisting of a virus claim 4 , a small multicellular organism claim 4 , DNA claim 4 , RNA claim 4 , a peptide claim 4 , a polypeptide claim 4 , a protein claim 4 , a carbohydrate claim 4 , a lipid claim 4 , tissue claim 4 , and combinations thereof.6. The method of wherein the o-quinone methide comprises a label that is detectable by a method selected from the group consisting of fluorescence claim 1 , phosphorescence claim 1 , radiation detection claim 1 , optical methods claim 1 , electrochemical methods claim 1 , surface plasmon resonance imaging (SPRi) claim 1 , and combinations thereof.7. The method of wherein the o-quinone methide comprises a detectable label comprising a probe.8. The method of wherein the probe comprises DNA claim 7 , a peptide claim 7 , a polypeptide claim 7 , a protein claim 7 , or a combination thereof.9. The method of wherein conditions effective comprise contacting in an aqueous solution claim 1 , suspension claim 1 , or dispersion.10. The method of further comprising ...

Подробнее
Номер записи: 55
31-10-2013 дата публикации

VASCULAR CLIP

Номер: US20130289588A1
Автор: Chelko Stephen P., Robertson Thomas P.
Принадлежит: University of Georgia Research Foundation, Inc.

The present disclosure provides a clip for application to a renal artery to induce hypertension. The clip includes a pair of arms between which is formed a slot. The arms are supported by a base portion. The clip may include various curved surfaces to prevent snagging and damage when applied to the renal artery. Also, the clip is preferably constructed of stock titanium rods to have a unitary and stiff construction. Further, the clip includes a pair of cylindrical suture openings that retain a suture passed therethrough after the clip is applied to the renal artery. The suture firmly retains the clip on the artery. 1. A vascular clip comprising:a pair of arms defining a slot extending therebetween;a base portion connecting the pair of arms; andat least one curved surface.2. The vascular clip of claim 1 , wherein the base portion defines an end portion of the slot.3. The vascular clip of claim 2 , wherein the base portion includes the curved surface and the curved surface defines the end portion of the slot.4. The vascular clip of claim 3 , wherein the pair of arms extend parallel to each other from the base portion.5. The vascular clip of claim 4 , wherein the pair of arms have a curved peripheral surface.6. The vascular clip of claim 5 , wherein the base portion extends between ends of the pair of arms and the clip has a U-shape.7. The vascular clip of claim 6 , wherein the base portion has an elliptical cross-section.8. The vascular clip of claim 7 , wherein the curved peripheral surface is a cylindrical surface.9. The vascular clip of claim 7 , wherein the curved peripheral surface extends over a portion of the base portion not defining the slot.10. The vascular clip of claim 1 , wherein at least one of the pair of arms includes the curved surface.11. The vascular clip of claim 10 , wherein the curved surface includes a medial bevel defining a peripheral edge of the slot.12. The vascular clip of claim 11 , wherein the curved surface includes a lateral bevel ...

Подробнее
Номер записи: 56
31-10-2013 дата публикации

MODIFICATION OF SUCROSE DISTRIBUTION IN PLANTS

Номер: US20130291229A1
Автор: Harding Scott A., Tsai Chung-Jui
Принадлежит: University of Georgia Research Foundation, Inc.

The present invention provides transgenic plant and methods of using them. In one embodiment, the methods include growing a transgenic plant under certain conditions, such as stress conditions, such as drought, heat, or salt, where the plant has decreased expression of a SUT polypeptide compared to a control plant. The transgenic plant may have a phenotype of increased growth, increased formation of woody tissue, increased drought tolerance, increased water use efficiency, increased nitrogen utilization efficiency, or a combination thereof, compared to the control plant. In another embodiment, the methods include using a transgenic plant to produce a pulp. 1. A method for using a transgenic plant comprising:growing a transgenic plant in drought conditions, wherein the plant comprises decreased expression of a SUT polypeptide compared to a control plant.2. The method of wherein the transgenic plant has a phenotype of increased growth claim 1 , increased formation of woody tissue claim 1 , increased drought tolerance claim 1 , increased water use efficiency claim 1 , increased nitrogen utilization efficiency claim 1 , or a combination thereof claim 1 , compared to the control plant.3. The method of wherein the SUT polypeptide has at least 80% amino acid sequence identity to SEQ ID NO:2.4. The method of wherein the expression of the SUT polypeptide is decreased in the transgenic plant by at least 10% when grown in drought conditions compared to the transgenic plant not grown in the stress condition.5. The method of wherein the plant is a dicot.6. The method of wherein the transgenic plant is a woody plant.7Populus.. The method of wherein the transgenic plant is a member of the genus8. A method for maintaining stem growth during exposure to a stress condition comprising growing a transgenic plant under stress conditions claim 6 , wherein the transgenic plant comprises decreased expression of a coding region encoding a SUT polypeptide compared to a control plant.9. The ...

Подробнее
Номер записи: 57
21-11-2013 дата публикации

Methods including latent 1,3-dipole-functional compounds and materials prepared thereby

Номер: US20130310570A1
Автор: Frederic Friscourt, Geert-Jan Boons, Ngalle Eric Mbua, Petr A. Ledin
Принадлежит: University of Georgia Research Foundation Inc UGARF

Methods that include latent 1,3-dipole-functional compounds are disclosed herein. The latent 1,3-dipole-functional compound (e.g., an oxime) can be used to form an active 1,3-dipole-functional compound (e.g., a nitrile oxide) that can be used to react with a cyclic alkyne in a dipolar cycloaddition reaction.

Подробнее
Номер записи: 58
28-11-2013 дата публикации

Anti-trypanosomal peptides and uses thereof

Номер: US20130315984A1
Автор: John M. Harrington, Stephen L. Hajduk
Принадлежит: University of Georgia Research Foundation Inc UGARF

The present invention provides methods of killing, inhibiting the growth, and/or inhibiting the reproduction of kinetoplastid protozoan with hydrophobic signal sequence peptides and compositions including such hydrophobic signal sequence peptides.

Подробнее
Номер записи: 59
02-01-2014 дата публикации

METHODS AND COMPOSITIONS FOR DEGRADING PECTIN

Номер: US20140004588A1
Автор: Doran Peterson Joy
Принадлежит: University of Georgia Research Foundation, Inc.

The present invention provides enriched polynucleotides, and enriched polypeptides having pectinase activity. The present invention also includes methods of using the polynucleotides and polypeptides described herein. For instance, the methods include producing a metabolic product, such as ethanol 134-. (canceled)35. A method for degrading pectin comprising:contacting a composition comprising pectin with a polypeptide having pectinase activity under conditions suitable for the degradation of the pectin, wherein the polypeptide comprises an amino acid sequence, wherein the amino acid sequence and the amino acid sequence of SEQ ID NO:4 have at least 80% identity, and wherein the pectin is degraded.36. The method of further comprising contacting the degraded pectin with a polypeptide having oligogalacturonate activity.37. The method of wherein the polypeptide is expressed by a genetically modified microbe claim 35 , and wherein the contacting comprises contacting the pectin with the genetically modified microbe.38. The method of wherein the genetically modified microbe expresses an exogenous polypeptide having oligogalacturonate activity.39. The method of wherein the genetically modified microbe produces ethanol.40. The method of wherein the composition comprises a lignocellulosic material.41. The method of wherein the lignocellulose material is obtained from a fruit or a vegetable.42. The method of wherein the microbe is a gram-negative microbe or a fungus.43E. coliS. cerevisiae.. The method of wherein the microbe is or44. The method of wherein the polypeptide is enriched. This application claims the benefit of U.S. Provisional Application Ser. No. 61/097,975, filed Sep. 18, 2008, and 61/179,570, filed May 19, 2009, each of which is incorporated by reference herein.The US Energy Independence and Security Act (EISA) of 2007 states that transportation fuel introduced into commerce in the US (annual average) contain at least 12.95 billion gallons of renewable fuels by ...

Подробнее
Номер записи: 60
09-01-2014 дата публикации

RECOMBINANT MUMPS VIRUS VACCINE

Номер: US20140010840A1
Автор: He Biao
Принадлежит: University of Georgia Research Foundation, Inc.

The present invention provides the complete genomic sequence of the epidemic mumps virus (MuV) strain MuV. Further, a reverse genetics system was constructed and used to rescue recombinant viral constructs that are attenuated compared to MuVand JL vaccine viruses. Such constructs include viral constructs lacking the open reading frame (ORF) of the SH gene (rMuVΔSH) and/or incapable of expressing the V protein (rMuVΔV). 1. An isolated nucleotide sequence comprising the cDNA sequence encoding the full length RNA genome of a mumps virus , wherein the isolated nucleotide sequence encodes a mumps virus unable to express a small hydrophobic (SH) protein product and/or express a V protein product.2. The isolated nucleotide sequence comprising the cDNA sequence encoding the full length RNA genome of a mumps virus of comprising a deletion of the open reading frame (ORF) encoding the SH protein claim 1 , a mutation converting a start codon into a stop codon claim 1 , or a mutation in the region between the ORF encoding the F polypeptide and the ORF encoding the SH polypeptide that disrupts transcription of the SH gene.3. The isolated nucleotide sequence comprising the cDNA sequence encoding the full length RNA genome of a mumps virus of comprising a deletion of the ORF encoding the SH protein.4. The isolated nucleotide sequence comprising the cDNA sequence encoding the full length RNA genome of a mumps virus of comprising a deletion of 156 nucleotides of the ORF encoding the SH protein.5. The isolated nucleotide sequence comprising the cDNA sequence encoding the full length RNA genome of a mumps virus of comprising one or more mutations to the V/I/P gene abrogating expression of the V protein.6. The isolated nucleotide sequence comprising the cDNA sequence encoding the full length RNA genome of a mumps virus of claim 5 , wherein the one or more mutations to the V/I/P gene abrogating expression of the V protein comprise the nucleotide sequence GAGGAGGG at the editing site in ...

Подробнее
Номер записи: 61
09-01-2014 дата публикации

Synthetic Lipid A Derivative

Номер: US20140011987A1
Автор: BOONS Geert-Jan
Принадлежит: University of Georgia Research Foundation, Inc.

The invention provides functionalized monosaccharides and disaccharides suitable for use in synthesizing a lipid A derivative, as well as methods for synthesizing and using a synthetic lipid A derivative. 2. The compound of wherein Ris tert-butyldimethylsilyl (TBS) or dimethylthexylsilyl (TDS).3. The compound of wherein Ris azido.4. The compound of wherein Ris an amino protecting group comprising 9-fluorenylmethoxycarbamate (Fmoc).5. The compound of wherein Ris a hydroxyl protecting group comprising allyloxycarbonate (Alloc).6. The compound of wherein Ris an amino protecting group comprising 9-fluorenylmethoxycarbamate (Fmoc).7. The compound of wherein Ris a hydroxyl protecting group comprising allyloxycarbonate (Alloc) or levulinate (Lev).8. The compound of wherein Rand Rtogether form a ring comprising an acetal.10. The method of wherein selectively acylating the functionalized disaccharide comprises selectively acylating the functionalized disaccharide at two claim 9 , three or four of positions C-2 claim 9 , C-3 claim 9 , C-2′ and C-3′ of the functionalized disaccharide.11. The method of further comprising phosphorylating the functionalized disaccharide at either or both of the C-1 or C-4′ positions of the functionalized disaccharide.12. The method of further comprising contacting the functionalized disaccharide with a 3-deoxy-D-manno-oct-2-ulosonic acid (KDO) donor to yield a KDO glycoside at the C-6′ position of the functionalized disaccharide.13. The method of wherein Ris tert-butyldimethylsilyl (TBS) or dimethylthexylsilyl (TDS).14. The method of wherein Ris azido.15. The method of wherein Ris an amino protecting group comprising 9-fluorenylmethoxycarbamate (Fmoc).16. The method of wherein Ris a hydroxyl protecting group comprising allyloxycarbonate (Alloc). This application is a continuation application of U.S. application Ser. No. 12/676,253, filed Apr. 19, 2010, which is national stage application of International Application No. PCT/US2008/010394, filed ...

Подробнее
Номер записи: 62
20-02-2014 дата публикации

COMPOUNDS AND METHODS FOR CHEMICAL AND CHEMO-ENZYMATIC SYNTHESIS OF COMPLEX GLYCANS

Номер: US20140051603A1
Автор: BOONS Geert-Jan, Wang Zhen
Принадлежит: UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC

The present invention provides chemical and chemo-enzymatic methods for the synthesis of a wide array of complex asymmetric multi-antennary glycans. 2. The orthogonally protected oligosaccharide of further comprising a glycosidically linked glucosamine moiety in place of X claim 1 , wherein the ring hydroxyls on the glucosamine moiety are protected claim 1 , wherein the amine at the C-2 position of the glucosamine moiety is protected claim 1 , and wherein the anomeric position at the reducing end of the glucosamine moiety comprises X as in formula (I).3. The orthogonally protected oligosaccharide of further comprising a glycosidically linked glucosamine disaccharide in place of X claim 1 , wherein the ring hydroxyls on the glucosamine disaccharide are protected claim 1 , wherein the amines at both C-2 positions of the glucosamine disaccharide are protected claim 1 , and wherein the anomeric position at the reducing end of the glucosamine disaccharide comprises X as in formula (I).4. The orthogonally protected oligosaccharide of comprising a glycosidically linked fucose moiety at position C-6 of the terminal reducing glucosamine.5. The orthogonally protected oligosaccharide of wherein the orthogonal protecting group is selected from the group consisting of levulinoyl (Lev); 9-fluorenylmethoxycarbonyl (Fmoc); allyloxycarbonyl (Alloc); 2-naphthylmethyl (Nap); 1-naphthylmethyl (1-Nap); benzoyl (Bz); difluorobenzoyl (dfBz); pivaloyl levulinoyl (PivLev); pivaloyl benzoyl (PivBz); para-methoxybenzyl ether (PMB); methoxy phenyl ether (MP); allyl ether (Allyl); chloroacetyl ester (ClAc); trichloroacetyl ester (ClAc) claim 1 , trifluoroacetyl ester (FAc); and a silyl ether.6. An orthogonally protected oligosaccharide comprising an orthogonally protected oligosaccharide of .7. A method for making an oligosaccharide comprising:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'deprotecting the orthogonally protected oligosaccharide of by removing an orthogonal protecting group ...

Подробнее
Номер записи: 63
27-02-2014 дата публикации

METHODS FOR REACTING CYSTEINE RESIDUES IN PEPTIDES AND PROTEINS

Номер: US20140054163A1
Автор: Arumugam Selvanathan, BOONS Geert-Jan, Guo Jun, LIN NANNAN, NEKONGO EMMANUEL, POPIK VLADIMIR V.
Принадлежит: University of Georgia Research Foundation, Inc.

Methods for labeling or modifying cysteine residues in proteins and/or enzymes are disclosed. The methods include the reaction of an o-naphthoquinone methide with a thiol group of a cysteine residue of a protein or enzyme, which can be reversible in preferred embodiments. The o-naphthoquinone methide can conveniently be generated by irradiation of a precursor compound, preferably in an aqueous solution, suspension, or dispersion. 1. A method for labeling a protein having a thiol group , the method comprising:generating an o-naphthoquinone methide; andcontacting the o-naphthoquinone methide with the protein under conditions effective to form the labeled protein.2. The method of wherein the protein comprises a cysteine residue having the thiol group.3. The method of wherein the o-naphthoquinone methide is a 2-naphthoquinone-3-methide.5. The method of wherein the labeling method is reversible.6. The method of further comprising:irradiating the labeled protein under conditions effective to remove the label.7. The method of wherein conditions effective to remove the label comprise irradiating the labeled protein in a dilute solution.8. The method of wherein conditions effective to remove the label comprise irradiating the labeled protein in the presence of a polarized olefin.9. The method of wherein the polarized olefin is a vinyl ether.10. The method of wherein generating the o-naphthoquinone methide comprises:providing an o-naphthoquinone methide precursor compound; andirradiating the precursor compound under conditions effective to form the o-naphthoquinone methide.11. The method of wherein the precursor compound comprises a 3-hydroxymethyl-2-naphthol group.13. The method of wherein conditions effective to form the labeled protein comprise irradiating a molar excess of the precursor compound compared to the moles of thiol groups of the protein.14. The method of wherein the precursor compound is irradiated in the presence of the protein.15. A method for inhibiting an ...

Подробнее
Номер записи: 64
06-03-2014 дата публикации

Sorghum Maturity Gene and Uses Thereof in Modulating Photoperiod Sensitivity

Номер: US20140068815A1
Автор: Cuevas Hugo E., Paterson Andrew H., Tang Haibao
Принадлежит: University of Georgia Research Foundation, Inc.

Compositions relating to the sorghum maturity gene 1 (Ma1) and expression control sequences and methods of use thereof are provided. The compositions can be used to modulate flowering and photoperiod sensitivity in a plant. For example, methods are provided for developing genetically modified plant varieties in which flowering is accelerated, delayed or prevented. Methods are provided for treating a plant in order to delay flowering in the plant. Methods of placing a polynucleotide of interest, such a gene, under photoperiod sensitive control or photoperiod insensitive control are also provided. Screening methods are for identifying chemical agents that can modify photoperiod sensitivity are also disclosed. 1. A method of delaying flowering in a plant , comprising introducing to the plant a nucleic acid sequence that silences expression of a polynucleotide having the nucleic acid sequence SEQ ID NO: 1 , 2 , 3 , 4 , 5 , 6 , 7 , 9 , 10 , 11 , 12 , 13 , 28 , 29 , 30 , 31 , 32 , 33 or a complement thereof.2. The method of claim 1 , wherein the plant is a dicotyledon.3. The method of claim 1 , wherein the plant is a monocotyledon.4. The method of claim 1 , wherein the plant has lower photoperiod sensitivity compared to a control plant of the same species.5. A method of delaying flowering in plant comprising altering the sequence of SEQ ID NO: 14 claim 1 , 15 claim 1 , 16 claim 1 , 17 claim 1 , 18 claim 1 , 19 claim 1 , 20 claim 1 , 21 claim 1 , 22 claim 1 , 23 claim 1 , 24 claim 1 , 25 claim 1 , 26 or variants thereof in the plant.6. The method of claim 5 , wherein the altering comprises introducing one or more nucleic acid substitutions claim 5 , additions claim 5 , deletions or a combination thereof in SEQ ID NO: 14 claim 5 , 15 claim 5 , 16 claim 5 , 17 claim 5 , 18 claim 5 , 19 claim 5 , 20 claim 5 , 21 claim 5 , 22 claim 5 , 23 claim 5 , 24 claim 5 , 25 claim 5 , 26 or variants thereof.7. A method of increasing or accelerating flowering in a plant claim 5 , ...

Подробнее
Номер записи: 65
13-03-2014 дата публикации

METAL SILICATE NANOSHEETS, METHODS OF MAKING METAL SILICATE NANOSHEETS, AND METHODS OF USE

Номер: US20140072790A1
Автор: Barrett Christopher A., Johnson-McDaniel Darrah, Salguero Tina T.
Принадлежит: University of Georgia Research Foundation, Inc.

Embodiments of the present disclosure relate to the preparation of colloidal dispersions or suspensions of inorganic materials with nano-sized and nano-structured morphologies, preferably the nanosheet form, compositions produced by this method, and the like. 1. A composition , comprising:a metal silicate material having the dimensions of a nanosheet that is 1 to 10 monolayers thick and has one or two lateral dimensions of about 100 nm to 100 μm.2. The composition of claim 1 , wherein one layer of the metal silicate material has a thickness of about 1 to 3 nm.3. The composition of claim 1 , wherein the metal silicate pigment is selected from the group consisting of: an alkaline earth copper silicate and a gillespite-type series silicate.4. The composition of claim 3 , wherein the alkaline earth copper silicate is selected from the group consisting of: CaCuSiO claim 3 , SrCuSiO claim 3 , BaCuSiO claim 3 , and BaCuSiO.5. The composition of claim 3 , wherein the gillespite-type series silicate is defined by ABSiO claim 3 , wherein A is selected from Ca claim 3 , Ba claim 3 , and Sr claim 3 , and wherein B is selected from Cr and Fe.6. The composition of claim 1 , wherein the metal silicate material has the following formula: ACBDSiO claim 1 , where A=Ca claim 1 , Sr claim 1 , Ba; C=Zn claim 1 , Ti claim 1 , lanthanide element; 0≦x≦1; B=Cu claim 1 , Cr claim 1 , Fe; D=alkali metal; and 0≦y≦1.7. A method of making a metal silicate pigment claim 1 , comprising:delaminating bulk metal silicate to form a metal silicate material; andexfoliating the metal silicate material to form a metal silicate pigment having the dimensions of a nanosheet that is 1 to 10 monolayers thick and has one or two lateral dimensions of about 100 nm to 100 μm.8. The method of claim 7 , wherein delaminating includes mixing the bulk metal silicate with water at about 60 to 100° C. for about 1 to 10 days.9. The method of claim 7 , wherein exfoliating includes sonicating the metal silicate material in ...

Подробнее
Номер записи: 66
13-03-2014 дата публикации

Smart Recycling System

Номер: US20140074298A1
Автор: Jambeck Jenna, Johnsen Kyle, Mozo-Reyes Eliana, Sweet Colby
Принадлежит: THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION

Disclosed are smart recycling system (“SRS”) solutions for retrofit to a recycling bin. Exemplary embodiments include a housing for mounting to a recycling bin or lid. The housing may include an integrated circuit and other components such as photoelectric sensors positioned to recognize a recycling event (e.g., deposit of an item into the bin). A signal indicative of a recycling event is generated and associated data stored. Positive and/or negative feedback may be rendered on a display component for the benefit of the user and in response to the recycling event. Some embodiments may be operable to intermittently power components within the system so that power consumption is minimized. Signals generated by sensors in some embodiments may be parsed to recognize deposit of recyclables as opposed to deposit of non-recyclables or false positive events (e.g., a hand inserted to trip the sensor). 1. A smart recycling system (“SRS”) for retrofit to a recycling bin , the SRS comprising:a housing component for mounting to the recycling bin;one or more sensors for generating a signal triggered by a recycling event, wherein a recycling event comprises deposit of an item into the recycling bin;a monitor module in communication with the one or more sensors and configured to recognize a signal generated by the one or more sensors; and receiving notification from the monitor module that a recycling event has occurred;', 'storing data representative of the recycling event in a memory component; and', 'rendering a feedback via display component, wherein the feedback is associated with a particular recycling event., 'a processing component for2. The smart recycling system of claim 1 , wherein the one or more sensors comprises a photoelectric sensor.3. The smart recycling system of claim 2 , wherein the monitor module is further configured to distinguish a signal from the photoelectric sensor triggered by a recycling event associated with a recyclable item from a signal from the ...

Подробнее
Номер записи: 67
03-04-2014 дата публикации

PROKARYOTIC RNAi-LIKE SYSTEM AND METHODS OF USE

Номер: US20140093941A1
Автор: HALE CARYN R., TERNS MICHAEL P., TERNS REBECCA M.
Принадлежит: University of Georgia Research Foundation, Inc.

Provided herein are methods for inactivating a target polynucleotide. The methods use a psiRNA having a 5′ region and a 3′ region. The 5′ region includes, but is not limited to, 5 to 10 nucleotides chosen from a repeat from a CRISPR locus immediately upstream of a spacer. The 3′ region is substantially complementary to a portion of the target polynucleotide. The methods may be practiced in a prokaryotic microbe or in vitro. Also provided are polypeptides that have endonuclease activity in the presence of a psiRNA and a target polynucleotide, and methods for using the polypeptides. 1. A method for inactivating a target polynucleotide in a microbe comprising:introducing into the microbe a psiRNA comprising a 5′ region and a 3′ region, wherein the 5′ region is a psiRNA-tag of between 5 and 10 nucleotides chosen from a repeat from a CRISPR locus immediately upstream of a spacer, wherein the 3′ region comprises between 18 and 75 nucleotides, and wherein the 3′ region is substantially complementary to a portion of the target polynucleotide, wherein the target polynucleotide is inactivated.23-. (canceled)4. The method of wherein the target polynucleotide is cleaved in the region that is substantially complementary to the 3′ region.5. The method of wherein the psiRNA is introduced into the cell as an RNA polynucleotide.6. The method of wherein the psiRNA introduced into the cell as a DNA polynucleotide encoding the psiRNA.7. The method of wherein the psiRNA-tag is 8 nucleotides.8. (canceled)9. The method of wherein the target polynucleotide is an endogenous polynucleotide.10. (canceled)11. The method of wherein the psiRNA-tag nucleotide sequence is chosen from a CRISPR locus present in the microbe.12. (canceled)13. A method for cleaving a target polynucleotide comprising: a target polynucleotide;', 'a psiRNA comprising a 5′ region and a 3′ region, wherein the 5′ region is a psiRNA-tag of between 5 and 10 nucleotides chosen from a repeat from a CRISPR locus immediately ...

Подробнее
Номер записи: 68
10-04-2014 дата публикации

SPLIT BIRDCAGE COIL, DEVICES, AND METHODS

Номер: US20140097838A1
Автор: POTTER WILLIAM M., QUN ZHAO
Принадлежит: University of Georgia Research Foundation, Inc.

This disclosure describes, in one aspect, a device that includes a dual-tuned birdcage coil. The dual-tuned birdcage coil generally includes an inner multinuclear coil and a plurality of outer H coils separated from the inner coil. Also, the dual-tuned birdcage coil is generally configured so that the inner coil may be tuned independently of one or more of the outer coils. In some embodiments, the device may be configured to provide inductive coupling between the inner coil and the plurality of outer coils. In some embodiments, the multinuclear coil can include P, C, Na, N, O, or F, etc. In another aspect, this disclosure describes using the device to a generate magnetic resonance in a target. In some of cases, the method can further include creating an image of the target from the magnetic resonance generated by the device. 1. A device comprising:{'sup': '1', 'a dual-tuned birdcage coil comprising an inner multinuclear coil and a plurality of outer H coils separated from the inner coil, configured so that the inner coil may be tuned independently of one or more of the outer coils.'}2. The device of configured to provide inductive coupling between the inner coil and the plurality of outer coils.3. The device of wherein the multinuclear coil acquires signal from a nucleus other than H.4. The device of wherein the nucleus is a half-integer spin nucleus.5. The device of wherein the half-integer spin nucleus comprises P claim 4 , C claim 4 , N claim 4 , Na claim 4 , O claim 4 , or F6. A method comprising:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'generating magnetic resonance in a target using a device according to , wherein the inner coil is tuned independently of one or more of the outer coils.'}7. The method of wherein the target comprises body tissue.8. The method of claim 6 , further comprising detecting the magnetic resonance generated and digitizing the detected magnetic resonance.9. The method of claim 8 , further comprising creating an image from the ...

Подробнее
Номер записи: 69
10-04-2014 дата публикации

Paenibacillus Spp. and Methods for Fermentation of Lignocellulosic Materials

Номер: US20140099665A1
Автор: DECRESCENZO-HENRIKSEN EMILY, DORAN-PETERSON JOY
Принадлежит: University of Georgia Research Foundation, Inc.

Provided herein are methods for producing a fermentation product, such as ethanol, by co-culture of a member of the genus and an ethanologenic microbe, such as yeast or . Also provided are methods for making enzymes useful in the saccharification of a pretreated lignocellulosic material. The enzymes may be made by culturing a member of the genus in a composition suitable for production of such enzymes. An example of such a composition is a pretreated lignocellulosic material, for example, spent hydrolysates. Also provided are genetically modified members of the genus that have been genetically modified to not produce an antimicrobial, for instance, a polymyxin E. 1. A method for producing ethanol comprising:{'i': 'Paenibacillus', 'fermenting a composition comprising a pretreated lignocellulosic material, wherein the fermenting comprises contacting the composition with an ethanologenic microbe and a spp.'}2. The method of wherein the pretreated lignocellulosic material is present at a concentration of at least 10% solids.3. The method of wherein the fermenting is a simultaneous saccharification and fermentation.4. The method of wherein the ethanologenic microbe is a yeast.5Saccharomyces cerevisiae.. The method of wherein the yeast is6E. coli.. The method of wherein the ethanologenic microbe is7. The method of wherein the pretreated lignocellulosic material is pine.8Pinus taeda.. The method of wherein the pine is9PaenibacillisP. amylolyticus. The method of wherein the spp. is .10Paenibacillis. The method of wherein the spp. produces an enzyme having saccharifying activity when incubated on a medium comprising inorganic salts and a carbon source selected from glucose claim 1 , mannose claim 1 , xylose claim 1 , arabinose claim 1 , cellulose claim 1 , pectin claim 1 , starch claim 1 , xylan claim 1 , carboxymethylcellulose claim 1 , or a combination thereof.1113-. (canceled)14Paenibacillis. The method of wherein the contacting comprises inoculating the composition with ...

Подробнее
Номер записи: 70
03-01-2019 дата публикации

Ornamental Miscanthus sinensis Plant Named 'M77'

Номер: US20190008081P1
Автор: Hanna Wayne W., Schwartz Brian M.
Принадлежит: University of Georgia Research Foundation, Inc.

A new variety of plant named ‘M77’ produces a reduced number of seeds, making it less invasive. 1Miscanthus. A new and distinct cultivar of the plant named ‘M77’, as herein illustrated and described: Latin name of the genus and species of the plant claimed: ‘M77’ is a vegetatively propagated ornamental perennial cultivar of the genus and speciesVariety denomination: The new claimed is of the cultivar denominated ‘M77’.The present invention relates to a new and distinct cultivar of herein referred to as ‘M77’.The new is a product of a planned research, evaluation, and testing program conducted by the Inventors in Tifton, Ga. The objective of the research program is to create a new plant cultivar with reduced seed production. This cultivar is commercially important for its superior ornamental value and low seed production. These and other qualities are enumerated herein.There is a need for a seed sterile cultivar because cultivars produce higher seed set at higher elevations which tend to make this genus invasive. Unprotected roots of respective groups of 59, 44, and 49 ‘Gracillimus’ plants were irradiated with 4-, 8-, and 12-Kr, respectively, of Cobalt 60 radiation and transplanted to a test field at Tifton, Ga. on Apr. 21, 2006. On Aug. 9, 2006, 37 and 1 plants were observed to have survived the 4-Kr treatment, and one plant was observed to have survived the 8-Kr treatment. Seven plants from the 4-Kr treated plants had tillers with reduced seed set. One plant, designated 4-22-1-1, had tillers with no seed set. A culm from 4-22-1-1 was designated M8-4 in 2008 and observed for seed set thru 2009 at Tifton, Ga. (elevation about 350 ft.). In 2010, M8-4 was designated as M8 and planted at Blairsville, Ga. (elevation about 1,880 ft.) in 2010. In 2010, M8 produced one seed per inflorescence at Tifton, Ga. and no seed at Blairsville, Ga. while the ‘Gracillimus’ control plants produced numerous seeds per inflorescence at both locations in non-replicated tests. The seed ...

Подробнее
Номер записи: 71
12-01-2017 дата публикации

GLYCOPEPTIDE AND USES THEREOF

Номер: US20170008977A1
Автор: BOONS Geert-Jan, BUSKAS THERESE, Ingale Sampat, Wolfert Margaretha
Принадлежит: University of Georgia Research Foundation, Inc.

A glycolipopeptide comprising a carbohydrate component, a peptide component and a lipid component, for use as a therapeutic or prophylactic vaccine. Also provided are monoclonal and polyclonal antibodies that recognize the glycolipopeptide of the invention, as well as uses thereof. 1. A method for making an antibody comprising: at least one carbohydrate component comprising a B-epitope;', 'at least one peptide component comprising a T-epitope; and', 'at least one lipid component;', 'wherein the carbohydrate component comprises a saccharide selected from the group consisting of N-acetylglucosamine (GlcNAc), N-acetylgalactosamine (GalNAc), mannose, fucose and glucose; and, 'injecting into a mammal a glycolipopeptide comprisingisolating from the mammal at least one antibody that binds to the glycolipopeptide.221.-. (canceled)22. An antibody made according to the method of .23. A method for making an antibody comprising: at least one carbohydrate component comprising a B-epitope;', 'at least one peptide component comprising a T-epitope; and', 'at least one lipid component;', 'wherein the carbohydrate component comprises a saccharide selected from the group consisting of N-acetylglucosamine (GlcNAc), N-acetylgalactosamine (Ga1NAc), mannose, fucose and glucose;, 'injecting into a mammal a glycolipopeptide comprisingharvesting cells from the mammal;fusing the cells with myeloma cells to form hybridomas;selecting at least one hybridoma producing an antibody which binds to the glycolipopeptide; andisolating the antibody.24. The method of wherein the cells are spleen cells or lymph cells.25. The method of claim 23 , wherein the carbohydrate component comprises a self-antigen comprising the B-epitope.26. The method of claim 25 , wherein the self-antigen comprises a MUC-1 glycopeptide.27. The method of claim 23 , wherein the lipid component comprises PamCysSK claim 23 , wherein n=0 claim 23 , 1 claim 23 , 2 claim 23 , 3 claim 23 , 4 claim 23 , or 5.28. The method of claim 23 , ...

Подробнее
Номер записи: 72
09-01-2020 дата публикации

Methods and compositions related to increased viral production

Номер: US20200010830A1
Автор: Ralph A Tripp
Принадлежит: University of Georgia Research Foundation Inc UGARF

Disclosed are compositions and methods for increasing virus production.

Подробнее
Номер записи: 73
12-01-2017 дата публикации

SOUTHERN HIGHBUSH BLUEBERRY PLANT NAMED 'TH-917'

Номер: US20170013751P1
Автор: NeSmith D. Scott
Принадлежит: University of Georgia Research Foundation, Inc.

The new variety ‘TH-917’ is provided. The new and distinct variety ripens around mid May in southern Georgia and late May in middle Georgia. The fruit of the new variety ‘TH-917’ are large, firm, have good flavor and scar. The new variety ‘TH-917’ is vigorous with an estimated chilling requirement of about 500 to 550 hours at or below approximately 7° C. The asexually reproduced variety is reliably propagated vegetatively. 1. A new and distinct variety of southern highbush blueberry plant named ‘TH-917’, substantially as illustrated and described herein. This invention was made, in part, with U.S. Government support on behalf of U.S. Department of Agriculture, Hatch Act Grant No. GEO 01663. The U.S. Government has certain rights in this invention.‘TH-917’ is a southern highbush blueberry plant that is aThe new southern highbush blueberry plant claimed is of the variety denominated ‘TH-917’.The present invention relates to the discovery of a new and distinct cultivar of southern highbush blueberry plant botanically known as a and herein referred to as ‘TH-917’, as herein described and illustrated.The new blueberry plant variety ‘TH-917’ was selected in Griffin, Ga., in 2005. The new variety ‘TH-917’ ripens around mid-May in southern Georgia to late May in middle Georgia. The fruit of the new variety ‘TH-917’ are firm with good flavor and favorable scar. The new variety ‘TH-917’ has good yield and is vigorous with an estimated chilling requirement of about 500-550 hours at or below 7° C.Pedigree and history: ‘TH-917’ was selected in 2005 at the Georgia Experiment Station in Griffin, Ga., originating from a cross of ‘TH-653’בMillennia’ made by Dr. D. Scott NeSmith in 2002. The maternal parent (‘TH-653’) is a non-patented UGA breeding line derived from a cross of ‘Legacy’בTH-454’. Both ‘Legacy’ and ‘TH-454’ are not patented. The paternal parent, ‘Millennia’, is the subject of U.S. Plant Pat. No. 12,816. The selection ‘TH-917’ has been tested in asexually propagated ( ...

Подробнее
Номер записи: 74
11-01-2018 дата публикации

Pecan tree named 'Tanner'

Номер: US20180014440P1
Автор: Sparks Darrell
Принадлежит: University of Georgia Research Foundation, Inc.

A pecan tree distinguished by the following unique combination of characteristics: Consistent and acceptable fruit production, small fruit cluster, early nut maturity, large nut producing mammoth kernels with excellent color, and high resistance to scab fungus. 1. A new and distinct cultivar of pecan tree, as herein illustrated and described. Latin name of the genus and species of the plant:Variety denomination: ‘Tanner’.The present invention relates to a new and distinct variety of pecan tree named ‘Tanner’. My new tree can be used in gardens or for commercial production of pecan nuts. This new tree was selected from seedlings grown from controlled pollination at the University of Georgia Horticulture Farm in Watkinsville, Ga., in 1995. The ‘Tanner’ selection resulted from crossing ‘Desirable’ (unpatented) as the seed parent with ‘Pawnee’ (unpatented) as the pollen parent (). The question marks in after several of the pecan trees indicate that there is some uncertainty as to whether the identified tree is actually a part of the lineage of the new ‘Tanner’ pecan tree. The resulting tree was selected when growing in a cultivated area at Watkinsville, Ga.‘Tanner’ is distinguished from other pecan varieties known to the inventor due to the following unique combination of characteristics: Consistent and acceptable fruit production, small fruit cluster, early nut maturity, large nut producing mammoth kernels with excellent color and high resistance to scab fungus () and moderate resistance to black aphid (). ‘Tanner’ will fill a niche for large nuts similar in size to ‘Desirable’ but with the advantage of earlier maturity and high resistance to scab.Asexual reproduction of ‘Tanner’ by grafting, (top working) onto ‘Desirable’/seedling pecan trees in 2009 and 2012 in Albany, Ga. and onto ‘Cape Fear’ (unpatented) trees in 2009 in Leary, Ga. was performed in order to evaluate these trees. Asexual reproduction of ‘Tanner’ has shown that the forgoing characteristics come true ...

Подробнее
Номер записи: 75
21-01-2016 дата публикации

Berry impact recording device

Номер: US20160018431A1
Автор: Changying Li, Rui Xu
Принадлежит: University of Georgia Research Foundation Inc UGARF

Disclosed are various embodiments for a berry impact recording device. The berry impact recording device comprises a shell. Within the shell are at least a sensor and an integrated circuit. The sensor may be configured to detect an acceleration of the berry impact recording device. The integrated circuit may be configured to record the acceleration of the berry impact recording device and a timestamp corresponding to the acceleration.

Подробнее
Номер записи: 76
28-01-2016 дата публикации

NANOPARTICLES FOR MITOCHONDRIAL TRAFFICKING OF AGENTS

Номер: US20160022825A1
Автор: Dhar Shanta, Marrache Sean M.
Принадлежит: University of Georgia Research Foundation, Inc.

Nanoparticles include a core, a hydrophilic layer around the core, and one or more mitochondrial targeting moieties, and may optionally include one or more contrast agents or one or more therapeutic agents. For effective mitochondrial targeting the nanoparticles have a diameter of about 200 nm or less or have a zeta potential of about 0 mV or more. 1. A nanoparticle , comprising:a hydrophobic nanoparticle core;a hydrophilic layer surrounding the core; anda mitochondrial targeting moiety,wherein the nanoparticle has a diameter of about 200 nanometers or less and has a zeta potential of about 0 mV or greater.2. A nanoparticle according to claim 1 , wherein the nanoparticle has a diameter of from about 10 nanometers to about 250 nanometers.3. A nanoparticle according to claim 1 , wherein the nanoparticle has a diameter of from about 80 nanometers to about 100 nanometers.4. A nanoparticle according to claim 1 , wherein the nanoparticle has a zeta potential of about 1 mV or greater.5. A nanoparticle according to claim 1 , wherein the nanoparticle has a zeta potential of about 7 mV or greater.6. A nanoparticle according to claim 1 , wherein the nanoparticle has a zeta potential of about 20 mV or greater.7. A nanoparticle according to claim 1 , wherein the nanoparticle has a zeta potential of about 25 mV or greater.8. A nanoparticle according to claim 1 , wherein the mitochondrial targeting moiety comprises a moiety selected from the group consisting of a triphenyl phosophonium (TPP) moiety claim 1 , a Szeto-Shiller peptide claim 1 , and a rhodamine cation.9. A nanoparticle according to claim 1 , wherein the mitochondrial targeting moiety comprises a triphenyl phosophonium (TPP) moiety or a derivative thereof.10. A nanoparticle according to claim 1 , wherein the mitochondrial targeting moiety is attached to the core via a hydrophilic polymer moiety.11. A nanoparticle according to claim 10 , wherein the hydrophilic polymer moiety comprises PEG.12. A nanoparticle according ...

Подробнее
Номер записи: 77
17-04-2014 дата публикации

Stabilized bioactive peptides and methods of identification, synthesis, and use

Номер: US20140106341A1
Автор: Elliot Altman
Принадлежит: University of Georgia Research Foundation Inc UGARF

An intracellular selection system allows screening for peptide bioactivity and stability. Randomized recombinant peptides are screened for bioactivity in a tightly regulated expression system, preferably derived from the wild-type lac operon. Bioactive peptides thus identified are inherently protease- and peptidase-resistant. Also provided are bioactive peptides stabilized by a stabilizing group at the N-terminus, the C-terminus, or both. The stabilizing group can be a small stable protein, such as the Rop protein, glutathione sulfotransferase, thioredoxin, maltose binding protein, or glutathione reductase, an α-helical moiety, or one or more proline residues.

Подробнее
Номер записи: 78
22-01-2015 дата публикации

Pecan tree named 'TREADWELL'

Номер: US20150026848P1
Автор: Sparks Darrell
Принадлежит: University of Georgia Research Foundation, Inc.

A pecan tree distinguished by the following unique combination of characteristics: high precociousness and prolificacy, consistent production (if fruit thinned), early nut maturity, large nut size that produces mammoth halves, unusual high percentage kernel, exceptional kernel color, no kernel speckling has been observed, high resistance to N scorch, black pecan aphid, pecan leaf scorch mite, and good resistance to scab fungus. 1. A new and distinct cultivar of pecan tree, substantially as herein shown and described. ‘Treadwell’The present invention relates to a new and distinct variety of pecan tree named ‘Treadwell.’ My new tree can be used in gardens or for commercial production of pecan nuts. This new tree was selected from seedlings grown from controlled pollination at the University of Georgia Horticulture Farm in Watkinsville, Ga., in 1989. The ‘Treadwell’ selection resulted from crossing ‘Wichita’ (unpatented) as the seed parent with ‘Pawnee’ (unpatented) as the pollen parent. The resulting tree was selected when growing in a cultivated area at Watkinsville, Ga.‘Treadwell’ is distinguished from other pecan varieties known to the inventor due to the following unique combination of characteristics: high precociousness and prolificacy, consistent production (if fruit thinned), early nut maturity, large nut size that produces mammoth halves, unusual high percentage kernel, exceptional kernel color, immunity to kernel speckling, high resistance to N scorch, black pecan aphid, pecan leaf scorch mite, and good resistance to scab fungus.Asexual reproduction of ‘Treadwell’ by grafting, (top working) onto ‘Desirable’ (unpatented) pecan trees in 2002 and 2007 at locations in Leary, Ga. and Albany, Ga., respectively, was performed in order to evaluate these trees. Asexual propagation of ‘Treadwell’ pecan trees has also been performed at other locations in Georgia. Asexual reproduction of ‘Treadwell’ has shown that the forgoing characteristics come true to form, are ...

Подробнее
Номер записи: 79
22-01-2015 дата публикации

Pecan tree named 'HUFFMAN'

Номер: US20150026849P1
Автор: Sparks Darrell
Принадлежит: University of Georgia Research Foundation, Inc.

A pecan tree distinguished by the following unique combination of characteristics: Consistent and acceptable fruit production, small fruit cluster, moderately early nut maturity, large nut producing mammoth kernels with good color and no observed speckling, and no observed scab fungus. 1. A new and distinct cultivar of pecan tree, substantially as herein shown and described. ‘Huffman’The present invention relates to a new and distinct variety of pecan tree named ‘Huffman’. My new tree can be used in gardens or for commercial production of pecan nuts. This new tree was selected from seedlings grown from controlled pollination at the University of Georgia Horticulture Farm in Watkinsville, Ga., in 1990. The ‘Huffman’ selection resulted from crossing ‘Desirable’ (unpatented) as the seed parent with ‘Pawnee’ (unpatented) as the pollen parent. The resulting tree was selected when growing in a cultivated area at Watkinsville, Ga.‘Huffman’ is distinguished from other pecan varieties known to the inventor due to the following unique combination of characteristics: Consistent and acceptable fruit production, small fruit cluster, moderately early nut maturity, large nut producing mammoth kernels with good color and no observed speckling, and no observed scab fungus.Asexual reproduction of ‘Huffman’ by grafting, (top working) onto ‘Desirable’ pecan trees in 2005 and 2008 at a location in Albany, Ga. and in 2009 at a location in Leary, Ga. was performed in order to evaluate these trees. Asexual reproduction of ‘Huffman’ has shown that the forgoing characteristics come true to form, are firmly fixed, and are established and transmitted through succeeding propagations.Certain characteristics of this variety, such as growth and color, may change with changing environmental conditions (e.g., light, temperature, moisture, nutrient availability, or other factors). Color descriptions and other terminology are used in accordance with their ordinary dictionary descriptions, unless the ...

Подробнее
Номер записи: 80
30-01-2020 дата публикации

Bacteriophage-based electrochemical bacterial sensors, systems, and methods

Номер: US20200033340A1
Автор: Ramaraja P. Ramasamy, Yan Zhou
Принадлежит: University of Georgia Research Foundation Inc UGARF

The present disclosure includes methods and systems of detecting bacteria in a sample using phage-functionalized sensors, methods of enriching a sample with phage-functionalized magnetic particles, phage-functionalized magnetic particles and methods of making phage-functionalized magnetic particles.

Подробнее
Номер записи: 81
01-05-2014 дата публикации

Recombinant caldicellulosiruptor bescii and methods of use

Номер: US20140120592A1
Автор: DaeHwan Chung, Janet Westpheling, Minseok Cha
Принадлежит: University of Georgia Research Foundation Inc UGARF

This disclosure describes recombinant Caldicellulosiruptor bescii microbes designed to produce greater amounts of acetate, H 2 , and/or ethanol than a comparable wild type control. this disclosure also describes methods that generally include growing such recombinant microbes under conditions effective for the recombinant microbes to produce acetate, H 2 , and/or ethanol.

Подробнее
Номер записи: 82
09-02-2017 дата публикации

MITOCHONDRIA-TARGETING PLATINUM(IV) PRODRUG

Номер: US20170037071A1
Автор: Dhar Shanta, Marrache Sean, Pathak Rakesh
Принадлежит: University of Georgia Research Foundation, Inc.

Pt(IV) compounds include a mitochondria targeting moiety. One example of a Pt(IV) compound having a mitochondria targeting moiety is a Pt(IV) cisplatin-based compound. Upon reduction, the mitochondrial targeting moieties are released resulting in a Pt(II) therapeutic agent. Pt(IV) compounds including a mitochondria targeting moiety can be included in nanoparticles. The compounds or nanoparticles can be used to treat, for example, cancer. 1. A compound of comprising:a prodrug comprising a PT(IV) moiety, andone or more mitochondria targeting moieties conjugated to the to a Pt(IV) moiety of the prodrug,wherein reduction of Pt(IV) of the Pt(IV) moiety to Pt(II) releases the one or more mitochondria-targeting moieties from the compound and results in a Pt(II) therapeutic agent.2. A compound according to claim 1 , wherein the Pt(IV) prodrug comprises two mitochondria targeting moieties.4. A compound according to claim 3 , wherein when m=0 claim 3 , n=1 and when x=0 claim 3 , y=1.5. A compound according to or claim 3 , wherein one or two of Q claim 3 , Q claim 3 , Q claim 3 , and Qare negatively charged ligands.6. A compound according to claim 5 , wherein two of Q claim 5 , Q claim 5 , Q claim 5 , and Qare negatively charged ligands.7. A compound according to claim 5 , wherein each of Q claim 5 , Q claim 5 , Q claim 5 , and Qthat is a negatively charged ligand is selected from the group consisting of a halide claim 5 , an alkoxide claim 5 , an aryloxide claim 5 , a carboxylate claim 5 , and a sulfate.8. A compound according to claim 7 , wherein each of Q claim 7 , Q claim 7 , Q claim 7 , and Qthat is a negatively charged ligand is a halide.9. A compound according to claim 7 , wherein each of Q claim 7 , Q claim 7 , Q claim 7 , and Qthat is a negatively charged ligand is a chloride.10. A compound according to claim 3 , wherein one or two of Q claim 3 , Q claim 3 , Q claim 3 , and Qare neutral ligands.11. A compound according to claim 10 , wherein each of Q claim 10 , Q ...

Подробнее
Номер записи: 83
15-02-2018 дата публикации

PIV5-Based Amplifying Virus-Like Particles

Номер: US20180044644A1
Автор: He Biao
Принадлежит: University of Georgia Research Foundation, Inc.

Compositions, methods of use and methods of manufacture are provided for PIV5-based amplifying VLP (AVLP) that can deliver an expressible heterologous nucleotide sequence in target cells without producing progeny, and which demonstrate useful safety and therapeutic efficacy in multiple animal and human health applications, such as vaccination, gene therapy and cancer therapy. 1. An isolated polynucleotide which comprises:(i) at least a portion of each of PIV5 NP, V/P and L genes, and(ii) a heterologous non-PIV5 nucleotide sequence,wherein said polynucleotide lacks one or more of the PIV5 genes selected from the group consisting of M, F, SH and HN, or is incapable of expressing one or more of the PIV5 proteins selected from the group consisting of M, F, SH and HN.2. The polynucleotide of claim 1 , which comprises PIV5 NP claim 1 , V/P and L genes.3. The polynucleotide of claim 1 , which lacks PIV5 M gene or is incapable of expressing PIV5 M protein.4. The polynucleotide of claim 1 , wherein the heterologous non-PrV5 nucleotide sequence is inserted between the V/P and L genes.5. The polynucleotide of claim 1 , wherein one or all of the M claim 1 , F claim 1 , SH and HN PIV5 genes are replaced with the heterologous nucleotide sequence.6. The polynucleotide of claim 1 , wherein the heterologous nucleotide sequence comprises a selection marker.7. The polynucleotide of wherein the selection marker is Hyg or Hyg-TK.8. The polynucleotide of claim 1 , wherein the heterologous nucleotide sequence encodes a molecule selected from the group consisting of RNAi claim 1 , shRNA claim 1 , siRNA claim 1 , antisense oligonucleotide claim 1 , and ribozyme.9. The polynucleotide of claim 1 , wherein the heterologous nucleotide sequence is derived from a virus other than PIV5.10. The polynucleotide of claim 9 , wherein the heterologous nucleotide sequence is derived from a virus selected from the group consisting of influenza virus claim 9 , RSV claim 9 , and HIV.11. The polynucleotide ...

Подробнее
Номер записи: 84
15-05-2014 дата публикации

MICROBES AND METHODS FOR PRODUCING 1-PROPANOL

Номер: US20140134690A1
Автор: Jain Rachit, Yan Yajun
Принадлежит: University of Georgia Research Foundation, Inc.

Provided herein are microbes metabolically engineered to produce 1-propanol from a 1,2-propanediol intermediate. The microbes may include one or two pathways for production of 1-propanol from a 1,2-propanediol intermediate. Also provided herein are methods for using the microbes for the production of 1-propanol. 1. A microbe metabolically engineered to comprise at least one metabolic pathway for the production of 1-propanol from a 1 ,2-propanediol intermediate.2. The microbe of which produces 1-propanol using glucose as a carbon source.3. The microbe of metabolically engineered to overexpress an enzyme having methylglyoxal synthase activity.4. The microbe of metabolically engineered to overexpress an enzyme having secondary alcohol dehydrogenase activity.5. The microbe of wherein the secondary alcohol dehydrogenase comprises a diol dehydrogenase.6. The microbe of metabolically engineered to overexpress an enzyme having primary alcohol dehydrogenase activity.7. The microbe of wherein the enzyme having primary alcohol dehydrogenase activity comprises a methylglyoxal reductase.8. The microbe of wherein the enzyme having primary alcohol dehydrogenase comprises a lactaldehyde reductase.9. The microbe of wherein the primary alcohol dehydrogenase is native to the microbe.10. The microbe of comprising a first vector comprising a polynucleotide encoding at least one enzyme in a 1 claim 1 ,2-propanediol pathway claim 1 , the enzyme selected from one having methylglyoxal synthase activity claim 1 , one having secondary alcohol dehydrogenase activity claim 1 , and one having primary alcohol dehydrogenase activity.11. The microbe of wherein the first vector encodes methylglyoxal synthase claim 10 , a methylglyoxal reductase claim 10 , and a diol dehydrogenase.12. The microbe of wherein the first vector encodes an enzyme having methylglyoxal synthase activity and an enzyme having secondary alcohol dehydrogenase activity claim 10 , wherein the enzyme having secondary alcohol ...

Подробнее
Номер записи: 85
03-03-2016 дата публикации

PRECURSOR-DIRECTED BIOSYNTHESIS OF 5-HYDROXYTRYPTOPHAN

Номер: US20160060638A1
Автор: SUN Xinxiao, Yan Yajun
Принадлежит: University of Georgia Research Foundation, Inc.

The invention provides compounds, compositions, non-naturally occurring organisms, and methods useful for production of 5-hydroxytryptophan (5-HTP) in a microbial cell. A microbial system which includes at least one microbial cell, such as a bacterial cell or a yeast cell, is genetically engineered to express all or a portion of non-naturally occurring biosynthetic pathway that catalyzes the conversion of a simple carbon source, such as glucose, to 5-HTP. The invention can result in improved titers of 5-HTP and permits low-cost, large scale production. Methods of making and using the genetically engineered cells are also included in the invention. 1. A microbial system for the production of 5-hydroxytryptophan (5-HTP) comprising a plurality of genetically engineered cells comprising:a first genetically engineered cell comprising (i) at least one shikimate pathway enzyme, (ii) at least one enzyme having anthranilate synthase activity, and (iii) at least one enzyme having salicylate 5-hydroxylase (S5H) activity, which enzyme further has activity toward a non-natural anthranilate (AA) substrate; anda second genetically engineered cell comprising at least one enzyme having tryptophan biosynthesis activity, wherein the enzyme catalyzes the conversion of anthranilate (AA) to tryptophan and further has activity toward a non-natural 5-hydroxyanthranilate (5-HAA) substrate.2. The microbial system of wherein the enzyme having salicylate 5-hydroxylase (S5H) activity catalyzes the 5-hydroxylation of AA to yield 5-hydroxyanthranilate (5-HAA).3. The microbial system wherein the enzyme having tryptophan biosynthesis activity catalyzes the conversion of 5-HAA to 5-HTP.4. The microbial system of wherein the at least one shikimate pathway enzyme comprises a shikimate kinase claim 1 , a phosphoenolpyruvate synthase claim 1 , a transketolase claim 1 , and a 3-deoxy-D-arabinoheptulosonate 7-phosphate (DAHP) synthase.5Escherichia coli. The microbial system of wherein the first cell ...

Подробнее
Номер записи: 86
22-05-2014 дата публикации

Spiro[2.4]heptanes for Treatment of Flaviviridae Infections

Номер: US20140140957A1
Автор: Chu Chung K.
Принадлежит: University of Georgia Research Foundation, Inc.

Compounds, methods, and compositions for the treatment of infections in or exposure to humans and other host animals of Flaviviridae viruses, including HCV, that includes the administration of an effective amount of a spiro[2.4]heptane as described herein or a pharmaceutically acceptable salt or prodrug thereof, optionally in a pharmaceutically acceptable carrier, are provided. The spiro[2.4]heptane compounds either possess antiviral activity, or are metabolized to a compound that exhibits such activity. 2. The method of claim 1 , wherein Ris a pyrimidine or purine.3. The method of claim 2 , wherein the purine or pyrimidine is selected from the group consisting of cytosine claim 2 , 5-halocytosine claim 2 , uracil claim 2 , 5-halouracil claim 2 , 5-methylcytosine claim 2 , thymine claim 2 , adenine claim 2 , thymine claim 2 , guanine claim 2 , xanthine claim 2 , or hypoxanthine.4. The method of claim 2 , wherein the pyrimidine is 5-fluorocytosine or 5-fluorouracil.5. The method of claim 2 , wherein the pyrimidine is uracil.6. The method of claim 2 , wherein the pyrimidine is cytosine.7. The method of claim 1 , wherein Ris a phosphoramidate.8. The method of claim 2 , wherein Ris methyl claim 2 , Ris F claim 2 , and Ris OR.9. The method of claim 8 , wherein Ris uracil.10. The method of claim 9 , wherein Ris phosphoramidate.11. The method of claim 1 , wherein the spiro[2.4]heptane is administered orally.12. The method of claim 1 , wherein the spiro[2.4]heptane is administered transdermally.13. The method of claim 1 , wherein the spiro[2.4]heptane is administered via controlled release.14. The method of claim 1 , wherein the spiro[2.4]heptane is administered intravenously.15. The method of claim 1 , wherein the condition resulting from a hepatitis C infection is an antibody positive and antigen positive condition claim 1 , viral-based chronic liver inflammation claim 1 , liver cancer resulting from advanced hepatitis C claim 1 , cirrhosis claim 1 , or fatigue.16. The ...

Подробнее
Номер записи: 87
22-05-2014 дата публикации

Spiro[2.4]heptanes for Treatment of Flaviviridae Infections

Номер: US20140140958A1
Автор: Chu Chung K.
Принадлежит: University of Georgia Research Foundation, Inc.

Compounds, methods, and compositions for the treatment of infections in or exposure to humans and other host animals of Flaviviridae viruses, including HCV, that includes the administration of an effective amount of a spiro[2.4]heptane as described herein or a pharmaceutically acceptable salt or prodrug thereof, optionally in a pharmaceutically acceptable carrier, are provided. The spiro[2.4]heptane compounds either possess antiviral activity, or are metabolized to a compound that exhibits such activity. 3. The spiro[2.4]heptane of claim 1 , wherein B is a purine or pyrimidine selected from the group consisting of cytosine claim 1 , 5-halocytosine claim 1 , uracil claim 1 , 5-halouracil claim 1 , 5-methylcytosine claim 1 , thymine claim 1 , adenine claim 1 , thymine claim 1 , guanine claim 1 , xanthine claim 1 , or hypoxanthine.4. The spiro[2.4]heptane of claim 2 , wherein B is a purine or pyrimidine selected from the group consisting of cytosine claim 2 , 5-halocytosine claim 2 , uracil claim 2 , 5-halouracil claim 2 , 5-methylcytosine claim 2 , thymine claim 2 , adenine claim 2 , thymine claim 2 , guanine claim 2 , xanthine claim 2 , or hypoxanthine.5. The spiro[2.4]heptane of claim 1 , wherein the pyrimidine is 5-fluorocytosine or 5-fluorouracil.6. The spiro[2.4]heptane of claim 2 , wherein the pyrimidine is 5-fluorocytosine or 5-fluorouracil.7. The spiro[2.4]heptane of claim 1 , wherein the pyrimidine is uracil.8. The spiro[2.4]heptane of claim 2 , wherein the pyrimidine is uracil.9. The spiro[2.4]heptane of claim 1 , wherein the pyrimidine is cytosine.10. The spiro[2.4]heptane of claim 2 , wherein the pyrimidine is cytosine.11. The spiro[2.4]heptane of claim 1 , wherein Ris a phosphoramidate.12. The spiro[2.4]heptane of claim 2 , wherein Ris a phosphoramidate.13. The spiro[2.4]heptane of claim 1 , wherein Ris a pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein Ris H or mono claim 1 , di claim 1 ...

Подробнее
Номер записи: 88
01-03-2018 дата публикации

2'-FLUORO-6'-METHYLENE CARBOCYCLIC NUCLEOSIDES AND METHODS OF TREATING VIRAL INFECTIONS

Номер: US20180063059A1
Автор: Chu Chung K., Wang Jianing
Принадлежит: University of Georgia Research Foundation, Inc.

The present invention relates to 2′-Fluoro-6′-methylene carbocyclic nucleosides, pharmaceutical compositions containing these nucleosides and their use in the treatment or prophylaxis of a number of viral infections and secondary disease states and conditions thereof, especially including Hepatitis B virus (HBV) and secondary disease states and conditions thereof (cirrhosis and liver cancer), Heptatitis C virus (HCV), Herpes Simplex virus I and II (HSV-1 and HSV-2), cytomegalovirus (CMV), Varicella-Zoster Virus (VZV) and Epstein Barr virus (EBV) and secondary cancers which occur thereof (lymphoma, nasopharyngeal cancer, including drug resistant (especially including lamivudine and/or adefovir resistant) and other mutant forms of these viruses, especially HBV. 1100-. (canceled)102. The compound according to claim 101 , wherein Ris H.103. The compound according to wherein Rand Rare each independently H or a C-Cacyl group.104. The compound according to wherein Rand Rare each independently H or a C-Cacyl group.105. The compound according to wherein Ris H or a C-Cacyl group.106. The compound according to wherein Ris H or a C-Cacyl group.107. The compound according wherein R claim 101 , Rand Rare each H.109. The compound according to wherein Ris H claim 108 , an acyl group claim 108 , a phosphate claim 108 , phosphdiester or phosphoramidate group claim 108 , and Rand Rare each independently H or a C-Cacyl group.110. The compound according to wherein Ris an acyl group claim 108 , a phosphate claim 108 , phosphodiester or phosphoramidate group claim 108 , Ris H and Ris H or a C-Cacyl group.116. The compound according to wherein Ris H and Ris methyl or isopropyl.118. The compound according to wherein Ris H.119. The compound according to wherein Ris a C-Calkyl group.121. A pharmaceutical composition comprising an effective amount of a compound according to claim 101 , optionally in combination with a pharmaceutically acceptable carrier claim 101 , additive or excipient.122. A ...

Подробнее
Номер записи: 89
08-03-2018 дата публикации

MITOCHONDRIA-TARGETING PLATINUM(IV) PRODRUG

Номер: US20180066004A9
Автор: Dhar Shanta, Marrache Sean, Pathak Rakesh
Принадлежит: University of Georgia Research Foundation, Inc.

Pt(IV) compounds include a mitochondria targeting moiety. One example of a Pt(IV) compound having a mitochondria targeting moiety is a Pt(IV) cisplatin-based compound. Upon reduction, the mitochondrial targeting moieties are released resulting in a Pt(II) therapeutic agent. Pt(IV) compounds including a mitochondria targeting moiety can be included in nanoparticles. The compounds or nanoparticles can be used to treat, for example, cancer. 1. A compound comprising:a prodrug comprising a PT(IV) moiety, andone or more mitochondria targeting moieties conjugated to the Pt(IV) moiety of the prodrug,wherein reduction of Pt(IV) of the Pt(IV) moiety to Pt(II) releases the one or more mitochondria-targeting moieties from the compound and results in a Pt(II) therapeutic agent.2. A compound according to claim 1 , wherein the Pt(IV) prodrug comprises two mitochondria targeting moieties.4. A compound according to claim 3 , wherein when m=0 claim 3 , n=1 and when x=0 claim 3 , y=1.5. A compound according to claim 3 , wherein one or two of Q claim 3 , Q claim 3 , Q claim 3 , and Qare negatively charged ligands.6. A compound according to claim 5 , wherein two of Q claim 5 , Q claim 5 , Q claim 5 , and Qare negatively charged ligands.7. A compound according to claim 5 , wherein each of Q claim 5 , Q claim 5 , Q claim 5 , and Qthat is a negatively charged ligand is selected from the group consisting of a halide claim 5 , an alkoxide claim 5 , an aryloxide claim 5 , a carboxylate claim 5 , and a sulfate.8. A compound according to claim 7 , wherein each of Q claim 7 , Q claim 7 , Q claim 7 , and Qthat is a negatively charged ligand is a halide.9. A compound according to claim 7 , wherein each of Q claim 7 , Q claim 7 , Q claim 7 , and Qthat is a negatively charged ligand is a chloride.10. A compound according to claim 3 , wherein one or two of Q claim 3 , Q claim 3 , Q claim 3 , and Qare neutral ligands.11. A compound according to claim 10 , wherein each of Q claim 10 , Q claim 10 , Q ...

Подробнее
Номер записи: 90
29-05-2014 дата публикации

Functional Nanostructured "Jelly Rolls" with Nanosheet Components

Номер: US20140147473A1
Автор: Barrett Christopher Andrew, Manjare Manoj, Salguero Tina Trnka, Yao Kun, Zhao Yiping
Принадлежит: University of Georgia Research Foundation, Inc.

The present disclosure relates to multilayered materials that are designed to roll spontaneously into micron-sized, cylindrical “jelly roll” or scroll structures. Specifically in this disclosure, at least one of the layers is comprised of a nanosheet material. 1. A method of making a functionalized multilayer micron-sized scroll structure comprising:depositing an aqueous solution of nanosheets onto a substrate;coating the nanosheet layer with at first layer of a material to form a multilayer structure using vapor deposition, wherein the first layer comprises a metal containing substance selected from the group consisting of: a pure metal, a metal oxide, a metal nitride, a metal oxynitride, a metal carbide, and a combination thereof;adding a solvent; andsonicating the multilayer material so that the multilayer material spontaneously forms a functionalized multilayer micron-sized scroll structure.2. The method of claim 1 , wherein the nanosheet comprises a material selected from the group consisting of: graphene oxide (GO) claim 1 , graphene claim 1 , MoS claim 1 , hexagonal boron nitride (BN) claim 1 , and a combination thereof.3. The method of claim 1 , wherein the material of the first layer is selected from the group consisting of: Ti claim 1 , Pt claim 1 , Fe claim 1 , Ni claim 1 , TiO claim 1 , FeO claim 1 , Si claim 1 , and a combination thereof;4. The method of claim 1 , wherein the multilayer material spontaneously forms a scroll structure by a detachment mechanism comprising a physical delamination process.5. The method of claim 1 , further comprising depositing a second layer of material on the first layer of material prior to adding the solvent.6. The method of claim 5 , wherein the second layer is comprised of a metal containing substance selected from the group consisting of: a pure metal claim 5 , a metal oxide claim 5 , a metal nitride claim 5 , and a combination thereof.7. The method of claim 5 , wherein the second layer is comprised of a material ...

Подробнее
Номер записи: 91
24-03-2022 дата публикации

Dietary early glycation products for treating and preventing autoimmune diseases

Номер: US20220087285A1
Автор: Tai L. Guo, Yingjia Chen
Принадлежит: University of Georgia Research Foundation Inc UGARF

Therefore, disclosed herein is a composition comprising dietary early glycation products (EGPs) with less than 1 wt % advanced glycation end products (AGEs). Also disclosed is a method for treating or preventing diabetes in a subject, such as type 1 diabetes, type 2 diabetes, or gestational diabetes, that involves administering to a subject in need thereof a composition disclosed herein.

Подробнее
Номер записи: 92
05-06-2014 дата публикации

CONFIGURABLE PROCESS CONTROL DEVICE WITH ELECTRONIC DISPLAY ASSEMBLY

Номер: US20140151587A1
Автор: LaFountain Robert Lynn
Принадлежит: General Equipment and Manufacturing Company, Inc., d/b/a TopWorx, Inc.

A configurable process control device, which includes a field device, such as a valve position controller, that can be configured by a user to emulate any one of a plurality of different types of process control devices, is provided with an electronic display assembly. The electronic display assembly is operatively connected with a control circuit that is arranged to respond to the specific configuration of the field device to cause the electronic display assembly to display information relevant to the specific type of control device the field device has been configured to emulate. The information may include safety certification information specific to each of the different types of process control devices that the field device can be configured to emulate. 1. A configurable process control device for use in a plurality of use environments , wherein at least one of a pre-defined plurality of certifications must be displayed in conjunction with the configurable process control device depending on which of the use environments the configurable process control device is to be used in , the configurable process control device comprising:a field device;a first control circuit operatively coupled to the field device, the first control circuit arranged to control the field device and arranged to be reconfigured by a user to allow the field device to selectively emulate any of a plurality of different process control device types;an electronic display assembly, the electronic display assembly arranged to selectively display different information; anda second control circuit, the second control circuit operatively coupled to the electronic display assembly and the first control circuit, the second control circuit having access to a plurality of different certification information sets, each certification information set corresponding to a different one of the plurality of different process control device types;wherein the second control circuit causes the electronic display ...

Подробнее
Номер записи: 93
05-03-2020 дата публикации

Peanut maturity grading systems and methods

Номер: US20200068816A1
Автор: Brian Boland, Donald Leo, Kyle Johnsen, Sahil Patel, Zhuo Zhao, Zion Tse
Принадлежит: University of Georgia Research Foundation Inc UGARF

The present disclosure provides peanut maturity grading systems and methods for quickly, efficiently, and objectively determining a peanut maturity grade for a crop of peanuts and determining an optimal harvest time for the crop. Embodiments of systems and methods of the present disclosure can be performed in the field or field-side and do not require assistance of a trained peanut grading specialist.

Подробнее
Номер записи: 94
05-03-2020 дата публикации

Avian reovirus vaccines

Номер: US20200069788A1
Автор: Holly S. Sellers
Принадлежит: University of Georgia Research Foundation Inc UGARF

The present invention relates to novel strains of avian reovirus that were isolated from clinical cases of viral arthritis/tenosynovitis in chickens in the southeast United States. The invention is directed to these novel group 1 and group 2 avian reoviruses, diagnostic assays using antibodies and/or nucleotide- or amino acid-specific components of such viruses, such as the S1 gene encoding the sigma C protein, and to vaccines that protect chickens from disease caused by such viruses.

Подробнее
Номер записи: 95
24-03-2022 дата публикации

Attenuated isolate of infectious bronchitis virus strain dmv1639

Номер: US20220090024A1
Автор: Brian J. Jordan, Mark W. Jackwood
Принадлежит: University of Georgia Research Foundation Inc UGARF

A heat attenuated infectious bronchitis virus (IBV) isolate of PDRC DMV/1639 deposited at the ATCC under Patent Designation PTA-12657 an progeny and derivatives thereof and compositions thereof are presented. Methods for administering the isolates and compositions as vaccines to the prevent virulent IBV infection in birds of the order Galliformes are also presented.

Подробнее
Номер записи: 96
19-03-2015 дата публикации

Spiro[2.4]heptanes for Treatment of Flaviviridae Infections

Номер: US20150079036A1
Автор: Chu Chung K.
Принадлежит: University of Georgia Research Foundation, Inc.

Compounds, methods, and compositions for the treatment of infections in or exposure to humans and other host animals of Flaviviridae viruses, including HCV, that includes the administration of an effective amount of a spiro[2.4]heptane as described herein or a pharmaceutically acceptable salt or prodrug thereof, optionally in a pharmaceutically acceptable carrier, are provided. The spiro[2.4]heptane compounds either possess antiviral activity, or are metabolized to a compound that exhibits such activity. 2. The method of claim 1 , wherein Ris a pyrimidine or purine.3. The method of claim 2 , wherein the purine or pyrimidine is selected from the group consisting of cytosine claim 2 , 5-halocytosine claim 2 , uracil claim 2 , 5-halouracil claim 2 , 5-methylcytosine claim 2 , thymine claim 2 , adenine claim 2 , thymine claim 2 , guanine claim 2 , xanthine claim 2 , or hypoxanthine.4. The method of claim 2 , wherein the pyrimidine is 5-fluorocytosine or 5-fluorouracil.5. The method of claim 2 , wherein the pyrimidine is uracil.6. The method of claim 2 , wherein the pyrimidine is cytosine.7. The method of claim 1 , wherein Ris a phosphoramidate.8. The method of claim 2 , wherein Ris methyl claim 2 , Ris F claim 2 , and Ris OR.9. The method of claim 8 , wherein Ris uracil.10. The method of claim 9 , wherein Ris a phosphoramidate.11. The method of claim 1 , wherein the spiro[2.4]heptane is administered orally.12. The method of claim 1 , wherein the spiro[2.4]heptane is administered transdermally.13. The method of claim 1 , wherein the spiro[2.4]heptane is administered via controlled release.14. The method of claim 1 , wherein the spiro[2.4]heptane is administered intravenously.15. The method of claim 1 , wherein the condition resulting from a hepatitis C infection is an antibody positive and antigen positive condition claim 1 , viral-based chronic liver inflammation claim 1 , liver cancer resulting from advanced hepatitis C claim 1 , cirrhosis claim 1 , or fatigue.16. The ...

Подробнее
Номер записи: 97
05-06-2014 дата публикации

GLYCOPROTEIN CANCER BIOMARKER

Номер: US20140154710A1
Автор: Abbott Karen L., Pierce James Michael
Принадлежит: University of Georgia Research Foundation, Inc.

The invention relates to glycoproteins having a cancer-specific glycoform. Cancer-specific glycoforms are useful in diagnostics and therapeutics. 1. A method for evaluating the presence , absence , nature or extent of ovarian cancer or a precancerous condition of the ovary , the method comprising:providing a biological sample obtained from a subject, the biological sample comprising glycoproteins;contacting the biological sample with a glycan-binding molecule specific for a glycan, under conditions that permit binding of the glycan-binding molecule to a glycoprotein comprising said glycan;detecting binding of the glycan-binding molecule to the glycoprotein to determine the presence, absence or amount of a cancer-specific glycoform of the glycoprotein in the biological sample, wherein said cancer-specific glycoform comprises the glycan and is indicative of ovarian cancer or a precancerous condition of the ovary;wherein the plurality of glycoproteins are selected from the group consisting of periostin (POSTN), biglycan (BGN), heparan sulfate proteoglycan 2 (HSPG2), lactate dehydrogenase A (LDHA), thrombospondin 1 (THBS1) serine protease inhibitor H1 (SERPINH1), lysosomal-associated membrane glycoprotein 1 (LAMP1), lectin galactosidase soluble binding protein 3 (LGALS3BP), complement factor B (CFB), fibulin 5 (FBLN5), mucin 5b (MUC5b), and lactotransferrin (LTF); andwherein the presence, absence or amount of the cancer-specific glycoform is indicative of the presence, absence, nature or extent of ovarian cancer or a precancerous condition of the ovary.2. The method of wherein the glycan-binding molecule comprises a detectable label.3. The method of wherein the glycan-binding molecule is selected from the group consisting of a lectin claim 1 , a glycospecific antibody claim 1 , a glycospecific aptamer claim 1 , a glycospecific peptide claim 1 , and a glycospecific small molecule.4Aleuria aurantiaDatura stramonium. The method of wherein the lectin comprises at least one ...

Подробнее
Номер записи: 98
16-03-2017 дата публикации

MODULAR SYSTEM FOR THE REAL TIME ASSESSMENT OF CRITICAL THINKING SKILLS

Номер: US20170076622A1
Автор: BROWN ANGELA K., DUCREST DAVID L., HODGES GEORGIA W., ROBERSTON THOMAS P.
Принадлежит: University of Georgia Research Foundation, Inc.

Disclosed are various embodiments for assisting students in a development of critical thinking skills pertinent to solving problems. An educational system may access predefined education modules from memory that facilitate an interaction between a student and a user interface. The user input provided by the student is measured in real-time such that an analysis platform may conduct a real-time evaluation of the user input. A heat map that visually depicts skills of the student is generated and may be rendered in an administrative user interface that may be accessed by a teacher or similar personnel. 1. A non-transitory computer-readable medium embodying a program executable in at least one computing device , comprising:code that accesses, in response to a request by at least one of a plurality of users, at least one of a plurality of predefined education modules from memory configured to facilitate an interaction between a respective one of the users and at least one user interface to assist the respective one of the users in a development of a respective skill;code that sends the at least one user interface to at least one of a plurality of client devices operated by the respective one of the users to be rendered in the client device, wherein the at least one user interface is configured to obtain user input data in real-time by measuring the interaction between the respective one of the users and the at least one user interface;code that sends, in response to accessing the user input data in real-time, the user input data to an administrative client device to be rendered in an administrative user interface, the administrative user interface being configured to switch among a plurality of interactions for each of the users and a corresponding user interface;code that generates a plurality of metrics for each of a plurality of skills, the plurality of metrics being determined by at least the user input data, wherein the metrics describe the development of the ...

Подробнее
Номер записи: 99
31-03-2022 дата публикации

BIMODAL NANOPARTICLE CONJUGATES FOR NON-INVASIVE CENTRAL NERVOUS SYSTEM TISSUE IMAGING

Номер: US20220096665A1
Автор: Chuang Yen-jun, MohanKumar Puliyur Seshadri, MohanKumar Sheba M.J.
Принадлежит: University of Georgia Research Foundation, Inc.

Ligand-bimodal nanoparticle conjugates capable of crossing the blood-brain barrier are disclosed. Methods of making and using the conjugates also are disclosed. The bimodal nanoparticle includes a polymeric matrix, one or more magnetic particles disposed within the polymeric matrix or conjugated to an outer surface of the polymeric matrix, and a dye disposed within the polymeric matrix. A ligand for a blood-brain barrier amino acid transporter is conjugated to the outer surface of the bimodal nanoparticle. 1. A ligand-bimodal nanoparticle conjugate , comprising:{'claim-text': ['a polymeric matrix,', 'one or more magnetic particles disposed within the polymeric matrix or conjugated to an outer surface of the polymeric matrix, and', 'a near-infrared dye disposed within the polymeric matrix; and'], '#text': 'a bimodal nanoparticle comprising'}a ligand for a blood-brain barrier amino acid transporter, the ligand conjugated to the outer surface of the bimodal nanoparticle.2. The ligand-bimodal nanoparticle conjugate of claim 1 , wherein the ligand comprises an amino acid precursor of a neurotransmitter.3. The ligand-bimodal nanoparticle conjugate of claim 1 , wherein the ligand comprises levodopa (L-DOPA) claim 1 , 5-hydroxytryptophan (5-HTP) claim 1 , or a combination thereof.4. The ligand-bimodal nanoparticle conjugate of claim 1 , wherein the one or more magnetic particles comprises a magnetic metal claim 1 , a compound comprising a magnetic metal claim 1 , or a combination thereof.5. The ligand-bimodal nanoparticle conjugate of claim 4 , wherein the one or more magnetic particles comprises FeO claim 4 , FeO claim 4 , Fe claim 4 , Gd claim 4 , or a combination thereof.6. The ligand-bimodal nanoparticle conjugate of claim 1 , wherein the near-infrared dye comprises silicon 2 claim 1 ,3-naphthalocyanine bis(trihexylsilyloxide) (NIR775).7. The ligand-bimodal nanoparticle conjugate of claim 1 , wherein the polymeric matrix comprises a semiconducting polymer and an ...

Подробнее
Номер записи: 100